{"content":"<li class=\"n-box-item date-title\" data-end=\"1508212799\" data-start=\"1508126400\" data-txt=\"Monday, December 23, 2019\">Monday, October 16, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3301350\" data-ts=\"1508194931\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMRX\" target=\"_blank\">AMRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301350-wsj-impax-labs-amneal-pharma-near-merger-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">WSJ: Impax Labs, Amneal Pharma near merger deal</a></h4><ul>     <li>Impax Laboratories (IPXL)&nbsp;<font color='green'>+6.2%</font> after-hours following a <em>WSJ</em> report that it is <a href=\"https://www.wsj.com/articles/impax-laboratories-and-amneal-pharmaceuticals-near-merger-agreement-1508188888\" target=\"_blank\">close to reaching a merger deal</a> with Amneal Pharmaceuticals that would create the fifth largest U.S. generic drug company by revenue.</li>     <li>The companies are in advanced talks on an all-stock deal that would hand IPXL shareholders 25% of a new publicly traded company and owners of closely-held Amneal the remainder, according to the report.</li>     <li>The new company reportedly would be called Amneal Pharmaceuticals and based in Bridgewater, N.J.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301350\" data-linked=\"WSJ: Impax Labs, Amneal Pharma near merger deal\" data-tweet=\"$AMRX - WSJ: Impax Labs, Amneal Pharma near merger deal https://seekingalpha.com/news/3301350-wsj-impax-labs-amneal-pharma-near-merger-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3301350-wsj-impax-labs-amneal-pharma-near-merger-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:02 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301345\" data-ts=\"1508190772\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KMG\" target=\"_blank\">KMG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301345-kmg-chemicals-launches-2_6m-share-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">KMG Chemicals launches 2.6M-share offering</a></h4><ul>     <li>KMG&nbsp;Chemicals (NYSE:<a href='https://seekingalpha.com/symbol/KMG' title='KMG Chemicals, Inc.'>KMG</a>) says it has commenced a <a href=\"https://seekingalpha.com/pr/16969769-kmg-announces-common-stock-offering\" target=\"_blank\">public offering</a> of 2.6M common shares, with an underwriters option to purchase up to an additional 390K shares.</li>     <li>KMG says it plans to use the proceeds for general corporate purposes, which may include debt repayment and working capital.</li><li>Shares <font color='green'>+2.5%</font> after-hours after easily beating <a href=\"https://seekingalpha.com/news/3301288-kmg-chemicals-beats-0_16-beats-revenue\" target=\"_blank\">FQ4 earnings</a> expectations.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301345\" data-linked=\"KMG Chemicals launches 2.6M-share offering\" data-tweet=\"$KMG - KMG Chemicals launches 2.6M-share offering https://seekingalpha.com/news/3301345-kmg-chemicals-launches-2_6m-share-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3301345-kmg-chemicals-launches-2_6m-share-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:52 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301343\" data-ts=\"1508190067\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301343-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/IMDZ' title='Immune Design'>IMDZ</a> <font color='green'>+8.9%</font>. <a href='https://seekingalpha.com/symbol/SAVE' title='Spirit Airlines'>SAVE</a> <font color='green'>+5.0%</font>. <a href='https://seekingalpha.com/symbol/INFI' title='Infinity Pharmaceuticals, Inc.'>INFI</a> <font color='green'>+3.1%</font>. <a href='https://seekingalpha.com/symbol/KALV' title='KalVista Pharmaceticals, Inc.'>KALV</a> <font color='green'>+2.8%</font>. <a href='https://seekingalpha.com/symbol/STON' title='StoneMor Partners L.P.'>STON</a> <font color='green'>+1.8%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/BMI' title='Badger Meter, Inc.'>BMI</a> <font color='red'>-10.4%</font>. <a href='https://seekingalpha.com/symbol/BRO' title='Brown & Brown Insurance'>BRO</a> <font color='red'>-5.0%</font>. <a href='https://seekingalpha.com/symbol/SONC' title='Sonic Corp.'>SONC</a> <font color='red'>-2.2%</font>. <a href='https://seekingalpha.com/symbol/AOBC' title='American Outdoor Brands Corporation'>AOBC</a> <font color='red'>-2.1%</font>. <a href='https://seekingalpha.com/symbol/TNDM' title='Tandem Diabetes Care, Inc.'>TNDM</a> <font color='red'>-2.0%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301343\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$IMDZ $SAVE $INFI - After Hours Gainers / Losers https://seekingalpha.com/news/3301343-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3301343-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:41 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301342\" data-ts=\"1508190055\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEUM\" target=\"_blank\">TEUM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301342-pareteum-dips-after-filing-to-offer-10m-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pareteum dips after filing to offer 10M shares</a></h4><ul>   <li>Pareteum (<a href=\"http://seekingalpha.com/symbol/TEUM\" target=\"_blank\">TEUM</a> <font color='red'>-5%</font>) is <font color='red'>off 1.8%</font> after hours following a <a href=\"https://seekingalpha.com/filing/3729286\" target=\"_blank\">filing to offer 10M shares</a>.</li>    <li>It had filed for an offering of up to $12M in stock and warrants; in a new amendment, it's filing for $13.8M in common stock and $750,000 in stock underlying warrants.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301342\" data-linked=\"Pareteum dips after filing to offer 10M shares\" data-tweet=\"$TEUM - Pareteum dips after filing to offer 10M shares https://seekingalpha.com/news/3301342-pareteum-dips-after-filing-to-offer-10m-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3301342-pareteum-dips-after-filing-to-offer-10m-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:40 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301341\" data-ts=\"1508189845\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JD\" target=\"_blank\">JD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301341-jd-com-finance-unit-hires-ex-amazon-scientist-to-lead-ai-effort\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">JD.com finance unit hires ex-Amazon scientist to lead AI effort</a></h4><ul>   <li>JD.com (<a href=\"http://seekingalpha.com/symbol/JD\" target=\"_blank\">JD</a> <font color='green'>+2.5%</font>) has gone to an ex-Amazon science chief to take over its finance unit's artificial intelligence efforts.</li>    <li>JD Finance has tapped Bo Liefeng, formerly principal scientist at Amazon.com, to lead its AI lab, Bloomberg reports.</li>    <li>That lab will push into areas including image identification, voice recognition and man-machine conversation, according to the report.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301341\" data-linked=\"JD.com finance unit hires ex-Amazon scientist to lead AI effort\" data-tweet=\"$JD - JD.com finance unit hires ex-Amazon scientist to lead AI effort https://seekingalpha.com/news/3301341-jd-com-finance-unit-hires-ex-amazon-scientist-to-lead-ai-effort?source=tweet\" data-url=\"https://seekingalpha.com/news/3301341-jd-com-finance-unit-hires-ex-amazon-scientist-to-lead-ai-effort\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301329\" data-ts=\"1508187456\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMDZ\" target=\"_blank\">IMDZ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301329-immune-design-to-launch-pivotal-study-for-cancer-vaccine-candidate-cmb305-shares-ahead-9\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Immune Design to launch pivotal study for cancer vaccine candidate CMB305; shares ahead 9% after hours</a></h4><ul><li>Thinly traded micro cap Immune Design (NASDAQ:<a href='https://seekingalpha.com/symbol/IMDZ' title='Immune Design'>IMDZ</a>) is up&nbsp;<font color='green'>9%</font>&nbsp;after hours on light volume on the heels of its <a href=\"https://seekingalpha.com/pr/16969704-immune-design-announces-positive-fda-feedback-phase-3-clinical-trial-design-cmb305-synovial\" target=\"_blank\">announcement </a>that it plans to initiate a Phase 3 clinical trial assessing cancer vaccine candidate CMB305 in patients with unresectable/metastatic NY-ESO-1-positive synovial sarcoma who show no signs of progression after first-line chemo. The results will support a U.S. marketing application.</li><li>The study should commence in mid-2018 and will enroll ~248 subjects at least 12 years old. The co-primary endpoints will be progression-free survival &#40;PFS&#41;&nbsp;and overall survival &#40;OS&#41;.</li><li><a href=\"http://www.immunedesign.com/pipeline/\" target=\"_blank\">CMB305&nbsp;</a>is a prime-boost vaccine against NY-ESO-1-expressing tumors designed to generate an integrated anti-NY-ESO-1 response via its specific interaction with messengers between the innate and adaptive immune systems called&nbsp;<a href=\"https://en.wikipedia.org/wiki/Dendritic_cell\" target=\"_blank\">dendritic cells</a>. The company says its approach is different from other cancer vaccines.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301329\" data-linked=\"Immune Design to launch pivotal study for cancer vaccine candidate CMB305; shares ahead 9% after hours\" data-tweet=\"$IMDZ - Immune Design to launch pivotal study for cancer vaccine candidate CMB305; shares ahead 9% after hours https://seekingalpha.com/news/3301329-immune-design-to-launch-pivotal-study-for-cancer-vaccine-candidate-cmb305-shares-ahead-9?source=tweet\" data-url=\"https://seekingalpha.com/news/3301329-immune-design-to-launch-pivotal-study-for-cancer-vaccine-candidate-cmb305-shares-ahead-9\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301320\" data-ts=\"1508186886\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GOGL\" target=\"_blank\">GOGL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301320-golden-ocean-groupminus-2_35-on-capital-raise\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Golden Ocean Group -2.35% on capital raise</a></h4><ul><li>The company is looking to raise gross proceeds of $66M through a public offering of common stock directed at institutional buyers.</li><li>Another $34M of shares is to be issued to Hemen Holding in exchange for two modern Capesize vessels.</li><li>Source: <a href=\"https://seekingalpha.com/pr/16969646-b-gogl-b-announcement-commencement-equity-offering\" target=\"_blank\">Press Release</a></li><li><a href='https://seekingalpha.com/symbol/GOGL' title='Golden Ocean Group Limited'>GOGL</a>&nbsp;<font color='red'>-2.35%</font>&nbsp;after hours</li></ul><div class=\"tiny-share-widget\" data-id=\"3301320\" data-linked=\"Golden Ocean Group -2.35% on capital raise\" data-tweet=\"$GOGL - Golden Ocean Group -2.35% on capital raise https://seekingalpha.com/news/3301320-golden-ocean-groupminus-2_35-on-capital-raise?source=tweet\" data-url=\"https://seekingalpha.com/news/3301320-golden-ocean-groupminus-2_35-on-capital-raise\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:48 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301318\" data-ts=\"1508186799\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ABEO\" target=\"_blank\">ABEO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301318-abeona-launches-equity-offering-shares-down-1-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Abeona launches equity offering; shares down 1% after hours</a></h4><ul><li>Abeona Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ABEO' title='Abeona Therapeutics Inc.'>ABEO</a>) <a href=\"https://seekingalpha.com/pr/16969643-abeona-therapeutics-announces-public-offering-common-stock\" target=\"_blank\">initiates </a>a public offering of common stock. Price, volume and terms have yet to be announced.</li><li>Shares are off&nbsp;<font color='red'>1%</font>&nbsp;after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301318\" data-linked=\"Abeona launches equity offering; shares down 1% after hours\" data-tweet=\"$ABEO - Abeona launches equity offering; shares down 1% after hours https://seekingalpha.com/news/3301318-abeona-launches-equity-offering-shares-down-1-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3301318-abeona-launches-equity-offering-shares-down-1-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301308\" data-ts=\"1508186179\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MITK\" target=\"_blank\">MITK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301308-mitek-acquires-icar-to-expand-global-reach\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mitek acquires ICAR to expand global reach</a></h4><ul><li>        Mitek (NASDAQ:<a href='https://seekingalpha.com/symbol/MITK' title='Mitek Systems Inc.'>MITK</a>) <a href=\"http://investors.miteksystems.com/releasedetail.cfm?ReleaseID=1044098\" target=\"_blank\">announces</a> the acquisition of consumer identity verification company ICAR for $15M in a combination of cash and shares.</li><li>               ICAR provides verification solutions in Spain and Latin America, which expands Mitek&rsquo;s global reach.&nbsp;</li><li>               Mitek shares are&nbsp;<font color='green'>up 1.04%&nbsp;</font>aftermarket.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3301308\" data-linked=\"Mitek acquires ICAR to expand global reach\" data-tweet=\"$MITK - Mitek acquires ICAR to expand global reach https://seekingalpha.com/news/3301308-mitek-acquires-icar-to-expand-global-reach?source=tweet\" data-url=\"https://seekingalpha.com/news/3301308-mitek-acquires-icar-to-expand-global-reach\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301303\" data-ts=\"1508185618\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SONC\" target=\"_blank\">SONC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301303-sonic-lower-after-revenue-shortfall\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sonic lower after revenue shortfall</a></h4><ul>     <li>Sonic (NASDAQ:<a href='https://seekingalpha.com/symbol/SONC' title='Sonic Corp.'>SONC</a>) is <font color='red'>down 2.22%</font>&nbsp;in after-hours trading after <a href=\"https://seekingalpha.com/pr/16969673-sonic-fiscal-2017-earnings-per-share-increase-12-percent-driven-refranchising-gains-asset\" target=\"_blank\">FQ4</a> revenue falls short.</li>     <li>Same-store sales fell 3.3% during the quarter, including a 4.8% decline at company drive-in locations. \"Our weaker-than-expected same-store sales performance reflects the intense competitive environment and unfavorable weather we saw during the quarter, including the devastation caused by Hurricane Harvey,\" says Sonic CEO Cliff Hudson.</li>      <li>Drive-in margins increased by 230 basis points at company-owned locations.</li>     <li>For the fiscal year ahead, Sonic sees EPS growth of 5% to 10% to a range of $1.31 to $1.38 vs. $1.36 consensus.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3301293-sonic-beats-0_02-misses-revenue\" target=\"_blank\">Sonic beats by $0.02, misses on revenue</a> (Oct. 16)</li>    </ul><div class=\"tiny-share-widget\" data-id=\"3301303\" data-linked=\"Sonic lower after revenue shortfall\" data-tweet=\"$SONC - Sonic lower after revenue shortfall https://seekingalpha.com/news/3301303-sonic-lower-after-revenue-shortfall?source=tweet\" data-url=\"https://seekingalpha.com/news/3301303-sonic-lower-after-revenue-shortfall\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:26 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301298\" data-ts=\"1508185196\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NFLX\" target=\"_blank\">NFLX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301298-all-time-high-for-netflix-after-subscriber-growth-shines\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">All-time high for Netflix after subscriber growth shines</a></h4><ul> <li>Netflix (NASDAQ:<a href='https://seekingalpha.com/symbol/NFLX' title='Netflix, Inc.'>NFLX</a>) jumps to a new all-time high after posting Q3 results.</li> <li>The company reported 850K domestic streaming additions vs. 774K consensus.</li> <li>International streaming additions came in at 4.45M vs. 3.72M consensus.</li> <li>Total streamings adds were 5.30M for the quarter vs. 4.50M consensus.</li> <li>Q3 U.S. streaming contribution margin fell 140 bps Q/Q to 35.8% as some content deals closed earlier than anticipated. The international contribution margin rate was 4.7%. Q1 operating margin was 7.0% vs. 4.6% a year ago.</li> <li>Netflix on cash: \"Free cash flow in Q3 totaled -$465 million vs. -$506 million last year and -$608 million in Q2&rsquo;17. There is no change to our expectation for FCF of -$2.0 to -$2.5 billion for the full year 2017.\"</li> <li>Looking ahead, Netflix expects Q4 domestic streaming adds of 1.25M vs. 1.63M consensus and international streaming additions of 5.05M vs. 4.66M consensus.</li> <li>Source: <a href=\"https://ir.netflix.com/events.cfm\" target=\"_blank\">Netflix Q3 shareholder letter</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3301294-netflix-misses-0_03-beats-revenue\" target=\"_blank\">Netflix misses by $0.03, beats on revenue</a> (Oct. 16)</li> <li>NFLX <font color='green'>+1.64%</font> AH to $205.77.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301298\" data-linked=\"All-time high for Netflix after subscriber growth shines\" data-tweet=\"$NFLX - All-time high for Netflix after subscriber growth shines https://seekingalpha.com/news/3301298-all-time-high-for-netflix-after-subscriber-growth-shines?source=tweet\" data-url=\"https://seekingalpha.com/news/3301298-all-time-high-for-netflix-after-subscriber-growth-shines\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:19 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>121&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301294\" data-ts=\"1508184941\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NFLX\" target=\"_blank\">NFLX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301294-netflix-misses-0_03-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Netflix misses by $0.03, beats on revenue</a></h4><ul><li>Netflix (NASDAQ:<a href='https://seekingalpha.com/symbol/NFLX' title='Netflix, Inc.'>NFLX</a>): Q3 EPS of $0.29 <font color='red'>misses by $0.03</font>.</li><li>Revenue of $2.99B (+30.6% Y/Y) <font color='green'>beats by $20M</font>.</li><li>Shares <font color='green'>+2%</font>.</li><li><a href=\"http://files.shareholder.com/downloads/NFLX/5401884928x0x959841/8E7F87AB-2E5C-41DB-862B-E872EF39B039/Q3_17_Shareholder_Letter_COMBINED.pdf\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3301294\" data-linked=\"Netflix misses by $0.03, beats on revenue\" data-tweet=\"$NFLX - Netflix misses by $0.03, beats on revenue https://seekingalpha.com/news/3301294-netflix-misses-0_03-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3301294-netflix-misses-0_03-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:15 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>37&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301287\" data-ts=\"1508184918\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGN\" target=\"_blank\">AGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301287-allergan-restasis-patent-stoked-selloff-overdone-jpmorgan\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Allergan Restasis patent-stoked selloff overdone - JPMorgan</a></h4><ul><li>JPMorgan's Chris Schott says today's selloff in Allergan (<a href='https://seekingalpha.com/symbol/AGN' title='Allergan plc'>AGN</a> <font color='red'>-3.5%</font>) after a Texas district court invalidated its RESTASIS patents is overdone considering the company's \"very attractive fundamental story,\" upcoming catalysts and numerous pipeline readouts next year (OVERWEIGHT/$300).</li><li>Wells Fargo's David Maris agrees saying a generic alternative won't be launched in the U.S. before the company's appeal runs its course, 2019 at the earliest (OUTPERFORM/$276).</li><li>Cowen's Ken Cacciatore adds that RESTASIS is now completely removed from the company's valuation (OUTPERFORM/$400).</li><li>Deutsche Bank has cut its price target to $251 from $262 after accounting for 90% sales erosion in 2019 and 5% per year thereafter.</li><li>Source: Bloomberg</li><li>Previously: <a href=\"https://seekingalpha.com/news/3301249-u-s-court-invalidates-allergans-restasis-patents-shares-5-percent\" target=\"_blank\">U.S. court invalidates Allergan's Restasis patents; shares down 5%</a> (Oct. 16)</li></ul><div class=\"tiny-share-widget\" data-id=\"3301287\" data-linked=\"Allergan Restasis patent-stoked selloff overdone - JPMorgan\" data-tweet=\"$AGN - Allergan Restasis patent-stoked selloff overdone - JPMorgan https://seekingalpha.com/news/3301287-allergan-restasis-patent-stoked-selloff-overdone-jpmorgan?source=tweet\" data-url=\"https://seekingalpha.com/news/3301287-allergan-restasis-patent-stoked-selloff-overdone-jpmorgan\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:15 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>25&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301278\" data-ts=\"1508183879\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FENC\" target=\"_blank\">FENC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301278-fennecs-sodium-thiosulfate-reduced-ototoxicity-of-chemo-in-late-stage-pediatric-oncology\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fennec&#39;s sodium thiosulfate reduced ototoxicity of chemo in late-stage pediatric oncology study; investors unimpressed, shares down 15%</a></h4><ul><li>Thinly traded micro cap Fennec Pharmaceuticals (<a href='https://seekingalpha.com/symbol/FENC' title='Fennec Pharmaceuticals, Inc.'>FENC</a> <font color='red'>-14.9%</font>) slumps on double normal volume after it <a href=\"https://seekingalpha.com/pr/16968587-fennec-announces-positive-results-phase-3-siopel-6-study-pedmark-sodium-thiosulfate-presented\" target=\"_blank\">announced </a>updated results from a Phase 3 clinical trial, SIOPEL 6, evaluating the ability of lead candidate sodium thiosulfate &#40;STS&#41; to reduce ototoxicity in pediatric cancer patients receiving platinum-based chemotherapy (Cis), an Orphan Drug indication. The data were presented at the 49th Congress of the International Society of Pediatric Oncology in Washington, D.C.</li><li>Among 99 evaluable patients, 37% (n=20/54) of the Cis + STS group experienced hearing loss compared to 67% (30/45) in the Cis alone group (p=0.0033).</li><li>The company plans to submit marketing applications in the U.S. and Europe.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301278\" data-linked=\"Fennec&#39;s sodium thiosulfate reduced ototoxicity of chemo in late-stage pediatric oncology study; investors unimpressed, shares down 15%\" data-tweet=\"$FENC - Fennec&#39;s sodium thiosulfate reduced ototoxicity of chemo in late-stage pediatric oncology study; investors unimpressed, shares down 15% https://seekingalpha.com/news/3301278-fennecs-sodium-thiosulfate-reduced-ototoxicity-of-chemo-in-late-stage-pediatric-oncology?source=tweet\" data-url=\"https://seekingalpha.com/news/3301278-fennecs-sodium-thiosulfate-reduced-ototoxicity-of-chemo-in-late-stage-pediatric-oncology\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:57 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301277\" data-ts=\"1508183517\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SVU\" target=\"_blank\">SVU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301277-telsey-gloom-hangs-over-grocery-sector\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Telsey gloom hangs over grocery sector</a></h4><ul> <li>Grocery store stocks were hit today by a cut in estimates from Telsey on Supervalu (<a href='https://seekingalpha.com/symbol/SVU' title='SUPERVALU Inc.'>SVU</a> <font color='red'>-7.7%</font>) amid ongoing concerns over margin pressure.</li> <li>Decliners include Sprouts Farmers Market (<a href='https://seekingalpha.com/symbol/SFM' title='Sprouts Farmers Market'>SFM</a> <font color='red'>-2.7%</font>), Kroger (<a href='https://seekingalpha.com/symbol/KR' title='Kroger Co.'>KR</a> <font color='red'>-4%</font>), Ingles Markets (<a href='https://seekingalpha.com/symbol/IMKTA' title='Ingles Markets, Incorporated'>IMKTA</a> <font color='red'>-4.2%</font>) and Natural Vitamin Grocers Cottage (<a href='https://seekingalpha.com/symbol/NGVC' title='Natural Grocers'>NGVC</a> <font color='red'>-7.2%</font>).</li><li>The grocery sector has been very sensitive to cuts in EPS forecasts since the Amazon-Whole Foods deal was inked.</li> <li>Source: Bloomberg</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301277\" data-linked=\"Telsey gloom hangs over grocery sector\" data-tweet=\"$SVU $SVU $SFM - Telsey gloom hangs over grocery sector https://seekingalpha.com/news/3301277-telsey-gloom-hangs-over-grocery-sector?source=tweet\" data-url=\"https://seekingalpha.com/news/3301277-telsey-gloom-hangs-over-grocery-sector\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:51 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301276\" data-ts=\"1508182658\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/X\" target=\"_blank\">X</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301276-u-s-steel-likely-headed-lower-longbow-says\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">U.S. Steel likely headed lower, Longbow says</a></h4><ul>     <li>U.S. Steel (<a href='https://seekingalpha.com/symbol/X' title='United States Steel Corporation'>X</a> <font color='red'>-2.4%</font>) has <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/17/10/10181657/us-steel-investors-may-be-in-for-a-reality-check\" target=\"_blank\">limited upside</a> over the next several quarters, Longbow analysts predict, seeing a disconnect between positive investor sentiment and deteriorating market fundamentals, particularly in oil country tubular goods.</li>     <li>&ldquo;Over the past 2-3 weeks, our proprietary channel work has detected slower-than-expected demand trends, inventory drawdown pressure, and price vulnerability for the two main operating segments in the portfolio (domestic steel and tubular),&rdquo; Longbow's Chris Olin writes.</li>     <li>Longbow has dialed back its expectation for tubular demand in 2018 and is now calling for a total rig count reduction of 10%-15% next year.</li>     <li>The firm rates the stock at Neutral with no assigned price target.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301276\" data-linked=\"U.S. Steel likely headed lower, Longbow says\" data-tweet=\"$X - U.S. Steel likely headed lower, Longbow says https://seekingalpha.com/news/3301276-u-s-steel-likely-headed-lower-longbow-says?source=tweet\" data-url=\"https://seekingalpha.com/news/3301276-u-s-steel-likely-headed-lower-longbow-says\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301275\" data-ts=\"1508182654\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OPNT\" target=\"_blank\">OPNT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301275-opiant-registers-150m-mixed-shelf-offering-shares-down-13\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Opiant registers $150M mixed shelf offering; shares down 13%</a></h4><ul><li>Opiant Pharmaceuticals (<a href='https://seekingalpha.com/symbol/OPNT' title='Opiant Pharmaceuticals, Inc.'>OPNT</a> <font color='red'>-13.1%</font>) files an <a href=\"https://www.sec.gov/Archives/edgar/data/1385508/000162828017009900/opnt-102017xs3.htm\" target=\"_blank\">S-3</a> for a $150M mixed shelf offering. Proceeds will be used for general corporate purposes.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301275\" data-linked=\"Opiant registers $150M mixed shelf offering; shares down 13%\" data-tweet=\"$OPNT - Opiant registers $150M mixed shelf offering; shares down 13% https://seekingalpha.com/news/3301275-opiant-registers-150m-mixed-shelf-offering-shares-down-13?source=tweet\" data-url=\"https://seekingalpha.com/news/3301275-opiant-registers-150m-mixed-shelf-offering-shares-down-13\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301273\" data-ts=\"1508182361\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AIMT\" target=\"_blank\">AIMT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301273-aimmune-teams-up-regeneron-and-sanofi-on-ar101-and-dupixent-in-patients-peanut-allergy-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aimmune teams up with Regeneron and Sanofi on AR101 and Dupixent in patients with peanut allergy; shares up 4%</a></h4><ul><li>Aimmune Therapeutics (<a href='https://seekingalpha.com/symbol/AIMT' title='Aimmune Therapeutics'>AIMT</a> <font color='green'>+4.4%</font>) is up on over double normal volume in response to its <a href=\"https://seekingalpha.com/pr/16968713-aimmune-therapeutics-announces-clinical-collaboration-study-ar101-regeneron-sanofi-s\" target=\"_blank\">announcement </a>of a clinical trial collaboration with Regeneron Pharmaceuticals (<a href='https://seekingalpha.com/symbol/REGN' title='Regeneron Pharmaceuticals, Inc.'>REGN</a> <font color='green'>+0.9%</font>) and Sanofi (<a href='https://seekingalpha.com/symbol/SNY' title='Sanofi'>SNY</a> <font color='green'>+0.3%</font>) evaluating AR101 with adjunctive DUPIXENT (dupilumab) in patients with peanut allergy.</li><li>The planned Phase 2 study, expected to start next year, will assess patients' desensitization to peanut protein with AR101 when dupilumab or placebo is added. The primary endpoint will be tolerating a certain dose of peanut protein.</li><li><a href=\"http://www.aimmune.com/pipeline/\" target=\"_blank\">AR101</a>&nbsp;is an orally administered biologic that desensitizes patients with peanut allergy. Dupilumab is a fully human monoclonal antibody that binds (inhibits) to proinflammatory cytokines interleukin-4 (IL-4) and interleukin-13 (IL-13).</li></ul><div class=\"tiny-share-widget\" data-id=\"3301273\" data-linked=\"Aimmune teams up with Regeneron and Sanofi on AR101 and Dupixent in patients with peanut allergy; shares up 4%\" data-tweet=\"$AIMT $AIMT $REGN - Aimmune teams up with Regeneron and Sanofi on AR101 and Dupixent in patients with peanut allergy; shares up 4% https://seekingalpha.com/news/3301273-aimmune-teams-up-regeneron-and-sanofi-on-ar101-and-dupixent-in-patients-peanut-allergy-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3301273-aimmune-teams-up-regeneron-and-sanofi-on-ar101-and-dupixent-in-patients-peanut-allergy-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:32 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301274\" data-ts=\"1508182273\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WILC\" target=\"_blank\">WILC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301274-g-willi-food-names-new-cfo\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">G. Willi-Food names new CFO</a></h4><ul> <li>G. Willi-Food International (<a href='https://seekingalpha.com/symbol/WILC' title='G. Willi-Food International, Ltd.'>WILC</a> <font color='green'>+8.4%</font>)&nbsp;announces the appointment Amir Kaplan to the chief financial officer position. Kaplan has been the CFO of RSL Electronics since 2011.</li> <li>Interim CFO&nbsp;Yitschak Barabi will now work as&nbsp;controller and deputy chief financial officer.</li><li>Source: <a href=\"https://seekingalpha.com/pr/16969570-g-willi-food-announces-change-management\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3301274\" data-linked=\"G. Willi-Food names new CFO\" data-tweet=\"$WILC - G. Willi-Food names new CFO https://seekingalpha.com/news/3301274-g-willi-food-names-new-cfo?source=tweet\" data-url=\"https://seekingalpha.com/news/3301274-g-willi-food-names-new-cfo\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:31 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301249\" data-ts=\"1508181066\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGN\" target=\"_blank\">AGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301249-u-s-court-invalidates-allergans-restasis-patents-shares-down-5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">U.S. court invalidates Allergan&#39;s Restasis patents; shares down 5%</a></h4><ul><li>A Texas district court has <a href=\"http://www.reuters.com/article/us-usa-defense-bergdahl/u-s-army-sergeant-bergdahl-pleads-guilty-to-desertion-endangering-troops-idUSKBN1CL17U\" target=\"_blank\">ruled </a>that patents covering Allergan's (<a href='https://seekingalpha.com/symbol/AGN' title='Allergan plc'>AGN</a> <font color='red'>-5.1%</font>) dry eye med RESTASIS (Cyclosporine Ophthalmic Emulsion) are invalid due to obviousness. The ruling was made in a patent infringement case involving potential generic competitors Mylan N.V. (<a href='https://seekingalpha.com/symbol/MYL' title='Mylan Inc'>MYL</a> <font color='green'>+0.4%</font>) and Teva Pharmaceutical Industries (<a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a> <font color='red'>-2.2%</font>).</li><li>The patents at issue at the same ones that Allergan recently transferred to a Native American tribe, but it said that it wiould not invoke the tribe's sovereign immunity in federal court.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3294452-allergan-uses-legal-maneuver-sovereign-tribal-government-protect-restasis-patents\" target=\"_blank\">Allergan uses legal maneuver with sovereign tribal government to protect Restasis patents</a> (Sept. 8)</li><li><strong>Update</strong>: In a <a href=\"https://seekingalpha.com/pr/16969520-u-s-district-court-eastern-district-texas-issues-adverse-trial-decision-concerning-restasis\" target=\"_blank\">statement</a>, Allergan Chief Legal Officer Robert Bailey says, \"We are disappointed by the Federal District Court's decision on the RESTASIS&nbsp;patents. We are carefully reviewing the decision and are considering all options. Allergan remains committed to vigorously defending the intellectual property of our products, which allows us to continue to invest in developing and bringing forward new medicines for millions of patients.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3301249\" data-linked=\"U.S. court invalidates Allergan&#39;s Restasis patents; shares down 5%\" data-tweet=\"$AGN $AGN $MYL - U.S. court invalidates Allergan&#39;s Restasis patents; shares down 5% https://seekingalpha.com/news/3301249-u-s-court-invalidates-allergans-restasis-patents-shares-down-5?source=tweet\" data-url=\"https://seekingalpha.com/news/3301249-u-s-court-invalidates-allergans-restasis-patents-shares-down-5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:11 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>60&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301265\" data-ts=\"1508180499\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UTSI\" target=\"_blank\">UTSI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301265-utstarcomplus-4_2-to-multi-year-high-after-first-half-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">UTStarcom +4.2% to multi-year high after first-half earnings</a></h4><ul>   <li>UTStarcom (NASDAQ:<a href='https://seekingalpha.com/symbol/UTSI' title='UTStarcom, Inc.'>UTSI</a>) is <font color='green'>up 4.2%</font> and has tagged its highest point since the beginning of 2015 after <a href=\"https://seekingalpha.com/news/3301087-utstarcom-reports-1h-results\" target=\"_blank\">first-half results</a> where it grew revenues nearly 27% and doubled basic EPS.</li>    <li>Net income was $8.3M vs. a year-ago $3.8M, and EPS (GAAP basis) went to $0.24 from a year-ago $0.10. Non-GAAP EPS was $0.25, vs. a year-ago $0.16.</li>    <li>Revenue beat expectations thanks to higher sales in Japan and India.</li>    <li>&ldquo;We achieved strong gross and operating margins in the first half, which was a result of our continued focus on high-margin product revenues, operational efficiencies, and overall cost control,\" said CEO Tim Ti.</li>    <li>Cash from operations was $9.9M; as of June 30, the company had cash and equivalents of $92.3M.</li>    <li>For Q3, the company is expecting a typical seasonal slight decline to revenues of $23M-$25M.</li>    <li><a href=\"https://seekingalpha.com/pr/16968684-utstarcom-reports-unaudited-financial-results-first-half-2017\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3301265\" data-linked=\"UTStarcom +4.2% to multi-year high after first-half earnings\" data-tweet=\"$UTSI - UTStarcom +4.2% to multi-year high after first-half earnings https://seekingalpha.com/news/3301265-utstarcomplus-4_2-to-multi-year-high-after-first-half-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3301265-utstarcomplus-4_2-to-multi-year-high-after-first-half-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301263\" data-ts=\"1508180315\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GOLD\" target=\"_blank\">GOLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301263-randgold-resources-says-kibali-mine-on-track-for-production-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Randgold Resources says Kibali mine on track for production target</a></h4><ul>     <li>Randgold Resources (<a href='https://seekingalpha.com/symbol/GOLD' title='Barrick Gold Corporation'>GOLD</a> <font color='red'>-1.9%</font>) says its $2B Kibali gold mine in the Democratic Republic of Congo <a href=\"https://seekingalpha.com/pr/16969381-kibali-track-prepares-completion-ug\" target=\"_blank\">remains on track</a> to achieve its production target of 610K oz. this year, as underground operations and the integration and automation of the vertical shaft enter the final commissioning stage.</li>     <li>The mine is anticipating a significant increase in production once the final shaft commissioning, which remains on a tight schedule, has been completed, CEO Mark Bristow says.</li>     <li>The company says the only major capital project still in the works following the anticipated completion of the underground mine in Q4 would be Kibali's third new hydropower station.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301263\" data-linked=\"Randgold Resources says Kibali mine on track for production target\" data-tweet=\"$GOLD - Randgold Resources says Kibali mine on track for production target https://seekingalpha.com/news/3301263-randgold-resources-says-kibali-mine-on-track-for-production-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3301263-randgold-resources-says-kibali-mine-on-track-for-production-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:58 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301262\" data-ts=\"1508180310\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HDP\" target=\"_blank\">HDP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301262-hortonworks-up-on-report-of-8_1m-government-contract\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hortonworks up on report of $8.1M government contract</a></h4><ul><li>Hortonworks (NASDAQ:<a href='https://seekingalpha.com/symbol/HDP' title='Hortonworks'>HDP</a>) shares are&nbsp;<font color='green'>up 2.47%&nbsp;</font>after JMP cites a $8.1M contract with the government.</li><li>More information when available.</li><li>Source: Bloomberg First Word</li><li>Update: Details courtesy <a href=\"https://thefly.com/landingPageNews.php?id=2623495&amp;headline=HDP-Hortonworks-analyst-commentary-at-JMP-Securities\" target=\"_blank\">The Fly:</a></li><li>        JMP Securities analyst Greg McDowell says his checks show Hortonworks might have signed the contract with the U.S. Department of Commerce Census Bureau and notes it would be Hortonworks&rsquo; largest federal contract.</li><li>                  McDowell says the contract, likely tied to the 2020 census, could provide an important use case for the Hadoop Distributed File System the company monitors.    </li><li>                  McDowell reiterates his Outperform rating and $18 price target.&nbsp; </li></ul><div class=\"tiny-share-widget\" data-id=\"3301262\" data-linked=\"Hortonworks up on report of $8.1M government contract\" data-tweet=\"$HDP - Hortonworks up on report of $8.1M government contract https://seekingalpha.com/news/3301262-hortonworks-up-on-report-of-8_1m-government-contract?source=tweet\" data-url=\"https://seekingalpha.com/news/3301262-hortonworks-up-on-report-of-8_1m-government-contract\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:58 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301259\" data-ts=\"1508180108\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301259-technology-top-gainers-losers-of-2-55-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 2:55 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/GRVY' title='GRAVITY Co., Ltd. - American depositary shares, each representing one'>GRVY</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/SIFY' title='Sify Technologies Limited'>SIFY</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/SOHU' title='Sohu.com Inc.'>SOHU</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/ASYS' title='Amtech Systems, Inc.'>ASYS</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/CCUR' title='Concurrent Computer Corporation'>OTC:CCUR</a> <font color='green'>+8%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/VERI' title='Veritone'>VERI</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/MTSI' title='MACOM Technology Solutions Holdings, Inc.'>MTSI</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/TRHC' title='Tabula Rasa HealthCare'>TRHC</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/RNVA' title='Rennova Health, Inc.'>OTCPK:RNVA</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/EGAN' title='eGain Communications Corp.'>EGAN</a> <font color='red'>-10%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301259\" data-linked=\"Technology - Top Gainers / Losers as of 2:55 pm\" data-tweet=\"$GRVY $SIFY $SOHU - Technology - Top Gainers / Losers as of 2:55 pm https://seekingalpha.com/news/3301259-technology-top-gainers-losers-of-2-55-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3301259-technology-top-gainers-losers-of-2-55-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301257\" data-ts=\"1508179666\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PSX\" target=\"_blank\">PSX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301257-phillips-66-andeavor-valero-downgraded-jefferies-in-refiner-review\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Phillips 66, Andeavor, Valero downgraded at Jefferies in refiner review</a></h4><ul>     <li>The run-up in oil refiners' stocks likely <a href=\"http://www.barrons.com/articles/oil-is-the-refiners-rally-over-1508163188\" target=\"_blank\">has come to an end</a>, Jefferies analysts say, even though Hurricane Harvey highlighted \"the intrinsic value refiners warehouse during periods of volatility.\"</li>     <li>As a result, Jefferies downgrades Phillips 66 (<a href='https://seekingalpha.com/symbol/PSX' title='Phillips 66'>PSX</a> <font color='red'>-3.6%</font>) to Underperform from Hold with a $77 price target, saying the stock's premium valuation is unjustified \"with poor performance on the Freeport LPG export expected though at least 2018 [and] a delay in the CPChem project in-service due to Harvey.\"</li>     <li>The firm also cuts both Andeavor (<a href='https://seekingalpha.com/symbol/ANDV' title='Andeavor'>ANDV</a> <font color='red'>-1.4%</font>) and Valero (<a href='https://seekingalpha.com/symbol/VLO' title='Valero Energy Corporation'>VLO</a> <font color='red'>-0.9%</font>) to Hold from Buy, remaining cautious on the ANDV's ability to meet 2018 EBITDA guidance without additional dropdowns and saying VLO's high free cash flows already are baked into its share price.</li>     </ul><div class=\"tiny-share-widget\" data-id=\"3301257\" data-linked=\"Phillips 66, Andeavor, Valero downgraded at Jefferies in refiner review\" data-tweet=\"$PSX $PSX $ANDV - Phillips 66, Andeavor, Valero downgraded at Jefferies in refiner review https://seekingalpha.com/news/3301257-phillips-66-andeavor-valero-downgraded-jefferies-in-refiner-review?source=tweet\" data-url=\"https://seekingalpha.com/news/3301257-phillips-66-andeavor-valero-downgraded-jefferies-in-refiner-review\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:47 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301251\" data-ts=\"1508178244\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PCG\" target=\"_blank\">PCG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301251-pg-and-e-shares-overreacted-to-california-fire-risk-morgan-stanley-says\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PG&amp;E shares have overreacted to California fire risk, Morgan Stanley says</a></h4><ul>     <li>PG&amp;E&nbsp;(<a href='https://seekingalpha.com/symbol/PCG' title='PG&E Corporation'>PCG</a> <font color='red'>-8.2%</font>) remains <a href=\"https://seekingalpha.com/news/3301215-pg-and-e-extends-plunge-21-month-lows-worry-california-fire-liability\" target=\"_blank\">mired in steep losses</a> even as the stock is defended at Morgan Stanley in light of recent weakness related to the California wildfires.</li>     <li>Morgan Stanley analyst Stephen Byrd believes PG&amp;E <a href=\"http://thefly.com/thestreet/realmoney/index.php/PCGid2623430/PCG-PGE-shares-may-have-overreacted-to-California-fire-risk-says-Morgan-Stanley\" target=\"_blank\">shares likely have overreacted</a>, noting that the stock reflects ~$5.6B in fire-related damage, a total Byrd thinks is greater than likely would be incurred by its shareholders.</li>     <li>The firm maintains its Overweight rating on PCG but also believes fire-related liability worries will continue to be a significant overhang, as it will take many months for an investigation to be completed.</li>     <li><em>Schaeffer's</em> notes that a number of strikes are seeing heavy trading, <a href=\"http://www.schaeffersresearch.com/content/options/2017/10/16/options-traders-swarm-pge-stock-amid-wildfire-allegations\" target=\"_blank\">topped by the October 60 call</a>, and buy-to-open activity looks likely - meaning a number of bulls expect the stock to rebound back to the round $60 level before Friday's close, when the front-month contracts expire.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301251\" data-linked=\"PG&amp;E shares have overreacted to California fire risk, Morgan Stanley says\" data-tweet=\"$PCG - PG&amp;E shares have overreacted to California fire risk, Morgan Stanley says https://seekingalpha.com/news/3301251-pg-and-e-shares-overreacted-to-california-fire-risk-morgan-stanley-says?source=tweet\" data-url=\"https://seekingalpha.com/news/3301251-pg-and-e-shares-overreacted-to-california-fire-risk-morgan-stanley-says\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:24 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301248\" data-ts=\"1508177536\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TI\" target=\"_blank\">TI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301248-italy-pulls-trigger-on-golden-power-over-telecom-italia\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Italy pulls trigger on &#39;golden power&#39; over Telecom Italia</a></h4><ul>   <li>Italy has elected to <a href=\"https://finance.yahoo.com/news/italy-cabinet-exercises-golden-power-140046733.html\" target=\"_blank\">use its \"golden power\"</a> over Telecom Italia (<a href=\"http://seekingalpha.com/symbol/TI\" target=\"_blank\">TI</a> <font color='red'>-1.7%</font>) and its decision-making, a significant result of a longstanding debate over the growing power over the company by French media giant Vivendi (<a href=\"http://seekingalpha.com/symbol/VIVHY\" target=\"_blank\">VIVHY</a> <font color='red'>-0.7%</font>).</li><li>Vivendi had no comment in response.</li>    <li>As Vivendi has built its stake (now at 24%) and tightened its grip on Telecom Italia, the Italian government has considered getting involved and regarding Telecom Italia as a national strategic asset. That debate centered mostly on the definition of whether Vivendi had \"control\" of the incumbent telecom.</li>    <li>Rome has never exercised the power, which allows for it to veto actions including asset sales, mergers and any change of control. Prime Minister Paolo Gentiloni didn't offer details along with the decree.</li>    <li>Italian regulator Consob ruled that Vivendi had control at TI, while Vivendi <a href=\"https://seekingalpha.com/news/3295473-vivendi-appealing-italy-ruling-controls-telecom-italia\" target=\"_blank\">appealed that ruling</a> saying it only exercised \"management and coordination.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3301248\" data-linked=\"Italy pulls trigger on &#39;golden power&#39; over Telecom Italia\" data-tweet=\"$TI $TI $VIVHY - Italy pulls trigger on &#39;golden power&#39; over Telecom Italia https://seekingalpha.com/news/3301248-italy-pulls-trigger-on-golden-power-over-telecom-italia?source=tweet\" data-url=\"https://seekingalpha.com/news/3301248-italy-pulls-trigger-on-golden-power-over-telecom-italia\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:12 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301246\" data-ts=\"1508176844\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301246-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/RCON' title='Recon Technology, Ltd.'>RCON</a> <font color='green'>+122%</font>. <a href='https://seekingalpha.com/symbol/SNES' title='SenesTech'>SNES</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/XCO' title='EXCO Resources, Inc.'>XCO</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/HBM' title='Hudbay Minerals Inc Ordinary Sh'>HBM</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/CELP' title='Cypress Energy Partners, L.P.'>CELP</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/FMSA' title='Fairmount Santrol, Inc.'>FMSA</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/ROSE' title='Rosehill Resources Inc.'>ROSE</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/WWR' title='Westwater Resources, Inc.'>WWR</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/UAN' title='CVR Partners, LP'>UAN</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301246\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$RCON $SNES $XCO - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3301246-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3301246-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301242\" data-ts=\"1508176282\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SBH\" target=\"_blank\">SBH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301242-sally-beauty-holdings-rallies-after-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sally Beauty Holdings rallies after upgrade</a></h4><ul> <li>D.A. Davidson upgrades Sally Beauty Holdings (<a href='https://seekingalpha.com/symbol/SBH' title='Sally Beauty Holdings, Inc.'>SBH</a> <font color='green'>+1.5%</font>) to a Buy rating from Neutral.</li> <li>Analyst Linda Bolton Weiser calls the retailer somewhat Amazon proof and points to the lush free cash flow yield of 11%.</li> <li>The price target on SBH from Davidson rises to <a href=\"https://twitter.com/usratings/status/919921820001808386\" target=\"_blank\">$21</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301242\" data-linked=\"Sally Beauty Holdings rallies after upgrade\" data-tweet=\"$SBH - Sally Beauty Holdings rallies after upgrade https://seekingalpha.com/news/3301242-sally-beauty-holdings-rallies-after-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3301242-sally-beauty-holdings-rallies-after-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:51 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301239\" data-ts=\"1508175788\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HALO\" target=\"_blank\">HALO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301239-halozyme-launches-early-stage-study-of-pegph20-tecentriq-in-bile-duct-and-gallbladder-cancers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Halozyme launches early-stage study of PEGPH20 + Tecentriq in bile duct and gallbladder cancers; shares up 2%</a></h4><ul><li>Halozyme Therapeutics (<a href='https://seekingalpha.com/symbol/HALO' title='Halozyme Therapeutics, Inc.'>HALO</a> <font color='green'>+2.1%</font>) is up on average volume on the heels of its <a href=\"https://seekingalpha.com/pr/16968800-halozyme-initiates-clinical-trial-pegph20-anti-pdl1-immunotherapy-cholangiocarcinoma\" target=\"_blank\">initiation </a>of a Phase 1 clinical trial assessing the combination of PEGPH20 (pegvorhyaluronidase alfa) and Roche's (<a href='https://seekingalpha.com/symbol/RHHBY' title='Roche Holding Ltd ADR'>OTCQX:RHHBY</a> <font color='red'>-0.6%</font>) TECENTRIQ (atezolizumab) in patients with metastatic cholangiocarcinoma (bile duct cancer) and gallbladder adenocarcinoma.</li><li>The <a href=\"https://clinicaltrials.gov/ct2/show/NCT03267940?intr=pegph20&amp;spons=halozyme&amp;draw=1&amp;rank=7\" target=\"_blank\">Phase 1b/2 open-label study</a> will compare the combination with standard chemo (cisplatin and gemcitabine). According to ClinicalTrials.gov, the estimated primary completion date is March 2020.</li><li><a href=\"http://www.halozyme.com/technology-and-products/product-candidate/pegph20/default.aspx\" target=\"_blank\">PEGPH20</a>&nbsp;is an investigational drug administered intravenously that temporarily degrades hyaluronan, a chain of natural sugars that builds up around cancer cells inhibiting the effectiveness of cancer-killing therapies.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3278440-halozyme-1-percent-premarket-start-roche-study-pegph20-tecentriq-combo-pancreatic-cancer\" target=\"_blank\">Halozyme up 1% premarket on start of Roche study of PEGPH20/Tecentriq combo in pancreatic cancer</a> (July 13)</li></ul><div class=\"tiny-share-widget\" data-id=\"3301239\" data-linked=\"Halozyme launches early-stage study of PEGPH20 + Tecentriq in bile duct and gallbladder cancers; shares up 2%\" data-tweet=\"$HALO $HALO $RHHBY - Halozyme launches early-stage study of PEGPH20 + Tecentriq in bile duct and gallbladder cancers; shares up 2% https://seekingalpha.com/news/3301239-halozyme-launches-early-stage-study-of-pegph20-tecentriq-in-bile-duct-and-gallbladder-cancers?source=tweet\" data-url=\"https://seekingalpha.com/news/3301239-halozyme-launches-early-stage-study-of-pegph20-tecentriq-in-bile-duct-and-gallbladder-cancers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:43 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301237\" data-ts=\"1508174879\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARQL\" target=\"_blank\">ARQL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301237-arqule-secures-15_7m-private-capital-raise-shares-up-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ArQule secures $15.7M private capital raise; shares up 2%</a></h4><ul><li>ArQule (<a href='https://seekingalpha.com/symbol/ARQL' title='ArQule, Inc.'>ARQL</a> <font color='green'>+1.9%</font>) inks an <a href=\"https://seekingalpha.com/pr/16968641-arqule-announces-15_7-million-private-placement-common-stock\" target=\"_blank\">agreement </a>with institutional investors for the direct sale of 13,938,651 shares of common stock and 3,123,674 warrants for net proceeds of ~$15.5M. The warrants are exercisable at $1.75 per common share.</li><li>Proceeds will fund clinical trials, working capital and general corporate purposes.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301237\" data-linked=\"ArQule secures $15.7M private capital raise; shares up 2%\" data-tweet=\"$ARQL - ArQule secures $15.7M private capital raise; shares up 2% https://seekingalpha.com/news/3301237-arqule-secures-15_7m-private-capital-raise-shares-up-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3301237-arqule-secures-15_7m-private-capital-raise-shares-up-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:27 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301236\" data-ts=\"1508174838\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301236-financials-top-5-gainers-losers-of-1-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/PN' title='Patriot National, Inc.'>PN</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/JP' title='Jupai Holdings'>JP</a> <font color='green'>+10%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/WHLR' title='Wheeler Real Estate Investment Trust'>WHLR</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/PMTS' title='CPI Card Group'>PMTS</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/FRSX' title='Foresight Autonomous Holdings Ltd.'>FRSX</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301236\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM\" data-tweet=\"$PN $JP $WHLR - Financials - Top 5 Gainers / Losers as of 1:00 PM https://seekingalpha.com/news/3301236-financials-top-5-gainers-losers-of-1-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3301236-financials-top-5-gainers-losers-of-1-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:27 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301234\" data-ts=\"1508174320\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CXRX-OLD\" target=\"_blank\">CXRX-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301234-concordia-defers-26m-interest-payment-for-30-days-shares-slip-5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Concordia defers $26M interest payment for 30 days; shares slip 5%</a></h4><ul><li>Thinly traded nano cap Concordia International (<a href='https://seekingalpha.com/symbol/CXRX-OLD' title='Concordia International Corp'>CXRX-OLD</a> <font color='red'>-5.3%</font>) is down on double normal volume on the heels of its <a href=\"https://seekingalpha.com/pr/16968819-concordia-international-corp-continues-discussions-stakeholders-defers-unsecured-interest\" target=\"_blank\">announcement</a> that it will use a 30-day grace period to defer paying $26M in interest on its $735M unsecured notes.</li><li>The company says it will use the extra time to continue discussions with lenders on restructuring the debt with the aim of creating a growth-enabling capital structure.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301234\" data-linked=\"Concordia defers $26M interest payment for 30 days; shares slip 5%\" data-tweet=\"$CXRX-OLD - Concordia defers $26M interest payment for 30 days; shares slip 5% https://seekingalpha.com/news/3301234-concordia-defers-26m-interest-payment-for-30-days-shares-slip-5?source=tweet\" data-url=\"https://seekingalpha.com/news/3301234-concordia-defers-26m-interest-payment-for-30-days-shares-slip-5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:18 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301229\" data-ts=\"1508173425\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IBIO\" target=\"_blank\">IBIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301229-aethlon-deal-stokes-ibio-shares-ahead-7\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aethlon deal stokes iBio, shares ahead 7%</a></h4><ul><li>Nano cap iBio (<a href='https://seekingalpha.com/symbol/IBIO' title='iBio, Inc.'>IBIO</a> <font color='green'>+6.7%</font>) is up a 4x spike on volume, although down 12% from the intraday high, in response to its <a href=\"https://seekingalpha.com/pr/16968707-aethlon-medical-announces-large-scale-production-collaboration\" target=\"_blank\">announced collaboration </a>with Aethlon Medical (<a href='https://seekingalpha.com/symbol/AEMD' title='Aethlon Medical, Inc.'>AEMD</a> <font color='red'>-5.3%</font>)&nbsp;to advance large-scale production of a component of the Aethlon Hemopurifier.</li><li>The partners will focus on producing large-scale volumes of a recombinant form of a plant-derived lectin called Galanthus nivalis agglutinin &#40;GNA&#41; that is immobilized within the Hemopurifier to bind infectious enveloped viruses.</li><li>Financial terms are not disclosed.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301229\" data-linked=\"Aethlon deal stokes iBio, shares ahead 7%\" data-tweet=\"$IBIO $IBIO $AEMD - Aethlon deal stokes iBio, shares ahead 7% https://seekingalpha.com/news/3301229-aethlon-deal-stokes-ibio-shares-ahead-7?source=tweet\" data-url=\"https://seekingalpha.com/news/3301229-aethlon-deal-stokes-ibio-shares-ahead-7\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301225\" data-ts=\"1508172522\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADBE\" target=\"_blank\">ADBE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301225-adobe-urges-users-patch-flash-after-malware-attack-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Adobe urges users patch Flash after malware attack; shares -</a></h4><ul><li>        Adobe Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/ADBE' title='Adobe Systems Incorporated'>ADBE</a>) <a href=\"http://www.reuters.com/article/us-adobe-systems-kaspersky/adobe-warns-that-hackers-are-exploiting-its-flash-software-idUSKBN1CL2C2\" target=\"_blank\">urges</a> users to patch its Flash multimedia software due to security vulnerabilities.</li><li>               Cybersecurity firm Kaspersky Lab reports that hackers used a previously unknown Flash weakness to plant malware on October 10.&nbsp;</li><li>               Targets included politicians, bloggers, reporters, and activists tied to Middle Eastern politics.&nbsp;</li><li>               The FinSpy malware used is a commercial product used by law enforcement and government agencies for surveillance.&nbsp;</li><li>               Adobe has released a patch to fix the problem. The company plans to retire Flash completely by 2020.&nbsp;</li><li>Adobe shares are&nbsp;<font color='red'>down 2.51%</font>.&nbsp;&nbsp;</li><li>Cybersecurity ETFs: <a href='https://seekingalpha.com/symbol/HACK' title='PureFunds ISE Cyber Security ETF'>HACK</a>, <a href='https://seekingalpha.com/symbol/CIBR' title='First Trust Nasdaq CEA Cybersecurity ETF'>CIBR</a>, <a href='https://seekingalpha.com/symbol/HAKK' title='Direxion Daily Cyber Security Bull 2x Shares ETF'>HAKK</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301225\" data-linked=\"Adobe urges users patch Flash after malware attack; shares -\" data-tweet=\"$ADBE $ADBE $HACK - Adobe urges users patch Flash after malware attack; shares - https://seekingalpha.com/news/3301225-adobe-urges-users-patch-flash-after-malware-attack-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3301225-adobe-urges-users-patch-flash-after-malware-attack-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:48 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301221\" data-ts=\"1508172402\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATHX\" target=\"_blank\">ATHX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301221-athersys-resolves-stem-cell-patent-dispute-garnet-bio-settles-for-non-exclusive-license\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Athersys resolves stem cell patent dispute with Garnet Bio, settles for non-exclusive license; shares down 5%</a></h4><ul><li>Athersys (<a href='https://seekingalpha.com/symbol/ATHX' title='Athersys, Inc.'>ATHX</a> <font color='red'>-4.6%</font>) has <a href=\"https://www.sec.gov/Archives/edgar/data/1368148/000119312517310296/d473928d8k.htm\" target=\"_blank\">agreed to settle</a> its patent fight with Garnet BioTherapeutics related to stem cell technologies.</li><li>Under the terms of the settlement, Garnet grants Athersys a global non-exclusive license license to Garnet patents related to the use of cells to treat or prevent disease. Athersys has agreed not to enforce its intellectual property rights against Garnet related to therapeutic agents derived from cells. Athersys will pay Garnet $500K and issue it 1M shares of common stock plus $250K in each of the next four quarters. It will deliver an additional 500K shares of stock to Garnet upon the issuance of a patent from Garnet's applications at the core of the dispute. No milestone payments or royalties are involved.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301221\" data-linked=\"Athersys resolves stem cell patent dispute with Garnet Bio, settles for non-exclusive license; shares down 5%\" data-tweet=\"$ATHX - Athersys resolves stem cell patent dispute with Garnet Bio, settles for non-exclusive license; shares down 5% https://seekingalpha.com/news/3301221-athersys-resolves-stem-cell-patent-dispute-garnet-bio-settles-for-non-exclusive-license?source=tweet\" data-url=\"https://seekingalpha.com/news/3301221-athersys-resolves-stem-cell-patent-dispute-garnet-bio-settles-for-non-exclusive-license\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>53&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301223\" data-ts=\"1508172216\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301223-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/RCON' title='Recon Technology, Ltd.'>RCON</a> <font color='green'>+106%</font>. <a href='https://seekingalpha.com/symbol/TRXC' title='TransEnterix, Inc.'>TRXC</a> <font color='green'>+71%</font>. <a href='https://seekingalpha.com/symbol/LBIX-OLD' title='Leading Brands Inc'>LBIX-OLD</a> <font color='green'>+30%</font>. <a href='https://seekingalpha.com/symbol/EXEL' title='Exelixis, Inc.'>EXEL</a> <font color='green'>+25%</font>. <a href='https://seekingalpha.com/symbol/RT' title='Ruby Tuesday, Inc.'>RT</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/SNES' title='SenesTech'>SNES</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/LINU-OLD' title='LiNiu Technology Group'>LINU-OLD</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/DTRM' title='Determine, Inc.'>OTC:DTRM</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/HIIQ' title='Health Insurance Innovations'>HIIQ</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/SIFY' title='Sify Technologies Limited'>SIFY</a> <font color='green'>+13%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/NHTC' title='Natural Health Trends Corp.'>NHTC</a> <font color='red'>-19%</font>. <a href='https://seekingalpha.com/symbol/AKER' title='Akers Biosciences Inc.'>AKER</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/ROKA' title='Roka Bioscience'>ROKA</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/TGTX' title='TG Therapeutics, Inc.'>TGTX</a> <font color='red'>-14%</font>. SHLD <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/SNAK' title='Inventure Foods, Inc.'>SNAK</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/TWMC' title='Trans World Entertainment Corp.'>TWMC</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/SGH' title='SMART Global Holdings'>SGH</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/PLSE' title='Pulse Biosciences'>PLSE</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/WHLR' title='Wheeler Real Estate Investment Trust'>WHLR</a> <font color='red'>-11%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301223\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$RCON $TRXC $LBIX-OLD - Midday Gainers / Losers https://seekingalpha.com/news/3301223-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3301223-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:43 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301219\" data-ts=\"1508171781\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TOSBF\" target=\"_blank\">TOSBF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301219-digitimes-toshiba-nand-production-shuts-temporarily-tightens-global-supply\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Digitimes: Toshiba NAND production shuts temporarily, tightens global supply</a></h4><ul><li>        Toshiba (<a href='https://seekingalpha.com/symbol/TOSBF' title='Toshiba Corp.'>OTCPK:TOSBF</a>, <a href='https://seekingalpha.com/symbol/TOSYY' title='Toshiba Corp. ADR'>OTCPK:TOSYY</a>) suspended NAND flash production at Japan facilities for three to six weeks after ransomware attacks, according to <a href=\"http://www.digitimes.com/news/a20171016PD205.html\" target=\"_blank\">Digitimes</a> sources.</li><li>               The shutdown reduced NAND flash production by almost 100K wafers, which could further tighten the global NAND supply that was expected to rebound in Q4.&nbsp;</li><li>               Top NAND players, by Q2 <a href=\"https://www.statista.com/statistics/275886/market-share-held-by-leading-nand-flash-memory-manufacturers-worldwide/\" target=\"_blank\">global market share</a>: Samsung (<a href='https://seekingalpha.com/symbol/SSNNF' title='Samsung Electronics Co., Ltd.'>OTC:SSNNF</a>, <a href='https://seekingalpha.com/symbol/SSNLF' title='Samsung Electronics Co., Ltd.'>OTC:SSNLF</a>), 35.6%; Toshiba, 17.5%; Western Digital (NYSE:<a href='https://seekingalpha.com/symbol/WDC' title='Western Digital Corporation'>WDC</a>), 17.5%; Micron (NASDAQ:<a href='https://seekingalpha.com/symbol/MU' title='Micron Technology Inc.'>MU</a>), 12.9%; SK Hynix, 9.9%; Intel (NASDAQ:<a href='https://seekingalpha.com/symbol/INTC' title='Intel Corporation'>INTC</a>), 6.6%.&nbsp;&nbsp;</li><li>Micron shares are&nbsp;<font color='green'>up 2.38%</font>.</li><li>Western Digital shares are&nbsp;<font color='red'>down 0.92%</font>&nbsp;since it has memory JVs with Toshiba.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3300732-ubs-lowers-western-digital-price-target-positive-mamr-potential\" target=\"_blank\">UBS lowers Western Digital price target, positive on MAMR potential</a> (Oct. 12)</li></ul><div class=\"tiny-share-widget\" data-id=\"3301219\" data-linked=\"Digitimes: Toshiba NAND production shuts temporarily, tightens global supply\" data-tweet=\"$TOSBF $TOSBF $TOSYY - Digitimes: Toshiba NAND production shuts temporarily, tightens global supply https://seekingalpha.com/news/3301219-digitimes-toshiba-nand-production-shuts-temporarily-tightens-global-supply?source=tweet\" data-url=\"https://seekingalpha.com/news/3301219-digitimes-toshiba-nand-production-shuts-temporarily-tightens-global-supply\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>25&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301215\" data-ts=\"1508170463\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PCG\" target=\"_blank\">PCG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301215-pg-and-e-extends-plunge-to-21-month-lows-on-worry-over-california-fire-liability\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PG&amp;E extends plunge to 21-month lows on worry over California fire liability</a></h4><ul>     <li>Pacific Gas &amp;&nbsp;Electric (<a href='https://seekingalpha.com/symbol/PCG' title='PG&E Corporation'>PCG</a> <font color='red'>-6.6%</font>) continues its <a href=\"https://seekingalpha.com/news/3301002-pg-and-e-extends-losses-following-fire-liability-disclosure-shares-now-minus-11-percent\" target=\"_blank\">precipitous decline</a> in the wake of the northern California fires, tumbling to its lowest since January 2016; shares have slumped 22.5% in just three days.</li>     <li>Goldman Sachs <a href=\"http://www.barrons.com/articles/pg-e-goldman-says-stock-reaction-overstated-but-downgrades-it-anyway-1508169264\" target=\"_blank\">removes PG&amp;E from its Conviction Buy List</a> and cuts its price target to $65 from $72 given the potential impact on cash flow from the California wildfires and with the stock lacking catalysts, but maintains its Buy rating as it sees the selloff as overdone.</li>     <li>Wells Fargo <a href=\"http://thefly.com/thestreet/realmoney/index.php/PCGid2623146/PCG-PGE-price-target-lowered-to--from--at-Wells-Fargo\" target=\"_blank\">trims its PCG price target</a> to $67 from $79 to reflect substantial uncertainty related to potential liabilities from the fires but reiterates its Outperform rating.</li>     <li>J.P. Morgan says shares are <a href=\"http://thefly.com/thestreet/realmoney/index.php/PCGid2623094/PCG-PGE-shares-still-worth--in-extreme-liability-scenario-says-JPMorgan\" target=\"_blank\">worth $60 in an \"extreme liability scenario\"</a> and assigns a 75% chance of the company being found liable for the wildfires; the firm cuts its price target to $66 from $76 while reiterating its Overweight rating but admits the wildfires will a \"major overhang\" for at least the better part of 2018.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301215\" data-linked=\"PG&amp;E extends plunge to 21-month lows on worry over California fire liability\" data-tweet=\"$PCG - PG&amp;E extends plunge to 21-month lows on worry over California fire liability https://seekingalpha.com/news/3301215-pg-and-e-extends-plunge-to-21-month-lows-on-worry-over-california-fire-liability?source=tweet\" data-url=\"https://seekingalpha.com/news/3301215-pg-and-e-extends-plunge-to-21-month-lows-on-worry-over-california-fire-liability\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:14 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301208\" data-ts=\"1508169848\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMPV\" target=\"_blank\">IMPV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301208-piper-jaffray-downgrades-imperva\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Piper Jaffray downgrades Imperva</a></h4><ul><li>        Piper Jaffray <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/17/10/10181411/management-changes-weakening-demand-put-imperva-in-peri\" target=\"_blank\">downgrades</a> Imperva (NASDAQ:<a href='https://seekingalpha.com/symbol/IMPV' title='Imperva, Inc.'>IMPV</a>) from Overweight to Neutral and cuts the price target from $58 to $42.</li><li>               Analyst Andrew Nowinski cites headwinds including deteriorating demand, loss of the CEO and CFO in Q3, potential downside for FY18 revenue estimates, and the current valuation.&nbsp;</li><li>                  Imperva shares are&nbsp;<font color='red'>down 5.85%.</font>&nbsp;   </li><li>Previously: <a href=\"https://seekingalpha.com/news/3300044-imperva-announces-interim-cfo\" target=\"_blank\">Imperva announces interim CFO</a> (Oct. 9)</li></ul><div class=\"tiny-share-widget\" data-id=\"3301208\" data-linked=\"Piper Jaffray downgrades Imperva\" data-tweet=\"$IMPV - Piper Jaffray downgrades Imperva https://seekingalpha.com/news/3301208-piper-jaffray-downgrades-imperva?source=tweet\" data-url=\"https://seekingalpha.com/news/3301208-piper-jaffray-downgrades-imperva\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:04 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301205\" data-ts=\"1508169678\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301205-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/LBIX-OLD' title='Leading Brands Inc'>LBIX-OLD</a> <font color='green'>+27%</font>. <a href='https://seekingalpha.com/symbol/LFVN' title='LifeVantage Corporation'>LFVN</a> <font color='green'>+10%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/NHTC' title='Natural Health Trends Corp.'>NHTC</a> <font color='red'>-20%</font>. <a href='https://seekingalpha.com/symbol/SNAK' title='Inventure Foods, Inc.'>SNAK</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/FTFT' title='Future Fintech Group Inc'>FTFT</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/SEED' title='Origin Agritech Limited'>SEED</a> <font color='red'>-5%</font>. <a href='https://seekingalpha.com/symbol/WKHS' title='Workhorse Group Inc.'>WKHS</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301205\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$LBIX-OLD $LFVN $NHTC - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3301205-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3301205-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301201\" data-ts=\"1508168210\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CCUR\" target=\"_blank\">CCUR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301201-concurrent-computer-corporation-agrees-to-sell-content-storage-unit\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Concurrent Computer Corporation agrees to sell content storage unit</a></h4><ul><li>Concurrent Computer Corporation (<a href='https://seekingalpha.com/symbol/CCUR' title='Concurrent Computer Corporation'>OTC:CCUR</a>) <a href=\"https://seekingalpha.com/pr/16968869-concurrent-enters-definitive-agreement-sell-content-delivery-and-storage-business-vecima\" target=\"_blank\">enters an agreement</a> to sell all assets of its Content Delivery &amp; Storage Business to Vecima Networks.</li><li>The deal has a base price of $29M subject to adjustments for normalized newt working capital.</li><li>Both boards have already approved the sale and it will close once all the appropriate regulators sign off.</li><li>Concurrent Computer shares are&nbsp;<font color='green'>up 8.28%</font>.</li><li>Update: Concurrent has the <a href=\"https://www.sec.gov/Archives/edgar/data/749038/000114420417052528/tv477004_8k.htm\" target=\"_blank\">right to terminate</a> the agreement if it decides on a superior proposal.Concurrent would have to pay a termination fee of $1.45M.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301201\" data-linked=\"Concurrent Computer Corporation agrees to sell content storage unit\" data-tweet=\"$CCUR - Concurrent Computer Corporation agrees to sell content storage unit https://seekingalpha.com/news/3301201-concurrent-computer-corporation-agrees-to-sell-content-storage-unit?source=tweet\" data-url=\"https://seekingalpha.com/news/3301201-concurrent-computer-corporation-agrees-to-sell-content-storage-unit\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>37&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301200\" data-ts=\"1508168143\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMPE\" target=\"_blank\">AMPE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301200-ampio-secures-6_75m-private-capital-raise-shares-down-6\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ampio secures $6.75M private capital raise; shares down 6%</a></h4><ul><li>Ampio Pharmaceuticals (<a href='https://seekingalpha.com/symbol/AMPE' title='Ampio Pharmaceuticals, Inc.'>AMPE</a> <font color='red'>-5.6%</font>) slips on almost double normal volume in response to its <a href=\"https://seekingalpha.com/pr/16968957-ampio-pharmaceuticals-inc-announces-pricing-registered-direct-offering\" target=\"_blank\">announced </a>sales of $6.75M of common stock to investors at $0.875 per share. Closing date is October 18.</li><li>Friday's close was $1.08.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301200\" data-linked=\"Ampio secures $6.75M private capital raise; shares down 6%\" data-tweet=\"$AMPE - Ampio secures $6.75M private capital raise; shares down 6% https://seekingalpha.com/news/3301200-ampio-secures-6_75m-private-capital-raise-shares-down-6?source=tweet\" data-url=\"https://seekingalpha.com/news/3301200-ampio-secures-6_75m-private-capital-raise-shares-down-6\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:35 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301197\" data-ts=\"1508167892\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AST\" target=\"_blank\">AST</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301197-asterias-bio-secures-10_4m-private-capital-raise-shares-ahead-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Asterias Bio secures $10.4M private capital raise; shares ahead 3%</a></h4><ul><li>Thinly traded micro cap Asterias Biotherapeutics (<a href='https://seekingalpha.com/symbol/AST' title='Asterias Biotherapeutics, Inc.'>AST</a> <font color='green'>+3.4%</font>) perks up on increased volume on the heels of its <a href=\"https://seekingalpha.com/pr/16968960-asterias-biotherapeutics-announces-10_4-million-registered-direct-offering\" target=\"_blank\">announced </a>private placement of 4M shares of Series A common stock at $2.60 per share. Closing date is October 18.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301197\" data-linked=\"Asterias Bio secures $10.4M private capital raise; shares ahead 3%\" data-tweet=\"$AST - Asterias Bio secures $10.4M private capital raise; shares ahead 3% https://seekingalpha.com/news/3301197-asterias-bio-secures-10_4m-private-capital-raise-shares-ahead-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3301197-asterias-bio-secures-10_4m-private-capital-raise-shares-ahead-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301196\" data-ts=\"1508167713\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NETE\" target=\"_blank\">NETE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301196-net-element-announces-ach-payment-launch\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Net Element announces ACH payment launch</a></h4><ul><li>        Net Element (NASDAQ:<a href='https://seekingalpha.com/symbol/NETE' title='Net Element International, Inc.'>NETE</a>) <a href=\"https://seekingalpha.com/pr/16968950-unified-payments-launches-day-ach-payment-processing-solution\" target=\"_blank\">announces</a> that its Unified Payments subsidiary launched Same-Day Automated Clearing House &#40;ACH&#41; payment processing solutions.</li><li>               According to the electronic payment association NACHA, ACH network volume accounted for more than 25B payments and $43T in transfers last year.&nbsp;</li><li>               Net Element shares are&nbsp;<font color='green'>up 11.41%</font>.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3301196\" data-linked=\"Net Element announces ACH payment launch\" data-tweet=\"$NETE - Net Element announces ACH payment launch https://seekingalpha.com/news/3301196-net-element-announces-ach-payment-launch?source=tweet\" data-url=\"https://seekingalpha.com/news/3301196-net-element-announces-ach-payment-launch\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301194\" data-ts=\"1508167422\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALGN\" target=\"_blank\">ALGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301194-align-tech-to-join-nasdaqminus-100-october-23-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Align Tech to join Nasdaq-100 October 23; shares up 1%</a></h4><ul><li>Align Technology (<a href='https://seekingalpha.com/symbol/ALGN' title='Align Technology, Inc.'>ALGN</a> <font color='green'>+0.8%</font>) will be the <a href=\"https://seekingalpha.com/pr/16968412-align-technology-inc-join-nasdaqminus-100-index-beginning-october-23-2017\" target=\"_blank\">newest membe</a>r of the Nasdaq-100 Index effective next Monday, October 23, replacing Mattel.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301194\" data-linked=\"Align Tech to join Nasdaq-100 October 23; shares up 1%\" data-tweet=\"$ALGN - Align Tech to join Nasdaq-100 October 23; shares up 1% https://seekingalpha.com/news/3301194-align-tech-to-join-nasdaqminus-100-october-23-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3301194-align-tech-to-join-nasdaqminus-100-october-23-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301191\" data-ts=\"1508166838\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DECK\" target=\"_blank\">DECK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301191-amazons-apparel-play-sized-up-investors\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amazon&#39;s apparel play sized up by investors</a></h4><ul> <li>Some retail stocks are trading lower in what could be a reaction to news that Amazon will source, design and sell its own athletic apparel line, baby clothes and underwear products.</li><li>The general tone from analysts is that a deeper reach by the e-commerce giant into apparel will magnify pricing pressure.</li> <li>Deckers Outdoor (<a href='https://seekingalpha.com/symbol/DECK' title='Deckers Outdoor Corporation'>DECK</a> <font color='red'>-2.8%</font>), Foot Locker (<a href='https://seekingalpha.com/symbol/FL' title='Foot Locker, Inc.'>FL</a> <font color='red'>-1.5%</font>), Hanesbrands (<a href='https://seekingalpha.com/symbol/HBI' title='Hanesbrands Inc.'>HBI</a> <font color='red'>-1.9%</font>), Lululemon (<a href='https://seekingalpha.com/symbol/LULU' title='Lululemon Athletica Inc.'>LULU</a> <font color='red'>-1.6%</font>), Canada Goose (<a href='https://seekingalpha.com/symbol/GOOS' title='Canada Goose Holdings'>GOOS</a> <font color='red'>-2%</font>), Carter's (<a href='https://seekingalpha.com/symbol/CRI' title='Carter&#39;s, Inc.'>CRI</a> <font color='red'>-1.3%</font>), PVH (<a href='https://seekingalpha.com/symbol/PVH' title='PVH Corp.'>PVH</a> <font color='red'>-0.2%</font>), Destination XL Group (<a href='https://seekingalpha.com/symbol/DXLG' title='Destination XL Group, Inc.'>DXLG</a> <font color='red'>-4.8%</font>), J. Jill (<a href='https://seekingalpha.com/symbol/JILL' title='J. Jill Group, Inc.'>JILL</a> <font color='red'>-5.7%</font>) and The Children's Place (<a href='https://seekingalpha.com/symbol/PLCE' title='The Children&#39;s Place Retail Stores, Inc.'>PLCE</a> <font color='red'>-3.8%</font>) are some of the retail names trading weak on the day.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3301017-bloomberg-amazon-planning-athletic-apparel-line-update\" target=\"_blank\">Bloomberg: Amazon planning athletic apparel line (update)</a> (Oct. 13)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3301191\" data-linked=\"Amazon&#39;s apparel play sized up by investors\" data-tweet=\"$DECK $DECK $FL - Amazon&#39;s apparel play sized up by investors https://seekingalpha.com/news/3301191-amazons-apparel-play-sized-up-investors?source=tweet\" data-url=\"https://seekingalpha.com/news/3301191-amazons-apparel-play-sized-up-investors\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301166\" data-ts=\"1508166054\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301166-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/TRXC' title='TransEnterix, Inc.'>TRXC</a> <font color='green'>+73%</font>. <a href='https://seekingalpha.com/symbol/EXEL' title='Exelixis, Inc.'>EXEL</a> <font color='green'>+28%</font>. <a href='https://seekingalpha.com/symbol/ARQL' title='ArQule, Inc.'>ARQL</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/FPRX' title='Five Prime Therapeutics, Inc.'>FPRX</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/NVCR' title='NovoCure'>NVCR</a> <font color='green'>+9%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ROKA' title='Roka Bioscience'>ROKA</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/AKER' title='Akers Biosciences Inc.'>AKER</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/BOLD' title='Audentes Therapeutics'>BOLD</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/TGTX' title='TG Therapeutics, Inc.'>TGTX</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/OREX' title='Orexigen Therapeutics, Inc.'>OREX</a> <font color='red'>-9%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301166\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$TRXC $EXEL $ARQL - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3301166-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3301166-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301183\" data-ts=\"1508165829\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BOLD\" target=\"_blank\">BOLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301183-audentes-therapeutics-under-pressure-from-downgrades-shares-slip-11\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Audentes Therapeutics under pressure from downgrades; shares slip 11%</a></h4><ul><li>Thinly traded small cap Audentes Therapeutics (<a href='https://seekingalpha.com/symbol/BOLD' title='Audentes Therapeutics'>BOLD</a> <font color='red'>-11.4%</font>) is under modest pressure on the heels of a downgrade to <a href=\"https://www.streetinsider.com/Analyst+Comments/UPDATE%3A+Evercore+ISI+Downgrades+Audentes+Therapeutics+%28BOLD%29+to+In+Line/13389958.html\" target=\"_blank\">Neutral </a>by Evercore ISI and to <a href=\"https://www.americanbankingnews.com/2017/10/11/zacks-investment-research-downgrades-audentes-therapeutics-inc-bold-to-sell.html\" target=\"_blank\">Sell </a>by Zacks Investment Research.</li><li>Preliminary data from a Phase 1/2 study of gene therapy AT132 in X-Linked Myotubular Myopathy are expected this quarter.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3296895-phase-1-2-study-underway-audentes-at132-rare-inherited-muscle-disorder-shares-2-percent\" target=\"_blank\">Phase 1/2 study underway on Audentes' AT132 in rare inherited muscle disorder; shares up 2%</a> (Sept. 21)</li></ul><div class=\"tiny-share-widget\" data-id=\"3301183\" data-linked=\"Audentes Therapeutics under pressure from downgrades; shares slip 11%\" data-tweet=\"$BOLD - Audentes Therapeutics under pressure from downgrades; shares slip 11% https://seekingalpha.com/news/3301183-audentes-therapeutics-under-pressure-from-downgrades-shares-slip-11?source=tweet\" data-url=\"https://seekingalpha.com/news/3301183-audentes-therapeutics-under-pressure-from-downgrades-shares-slip-11\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:57 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301181\" data-ts=\"1508165419\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARCB\" target=\"_blank\">ARCB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301181-trucking-stocks-in-retreat-after-cowen-weighs-in\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Trucking stocks in retreat after Cowen weighs in</a></h4><ul> <li>Cowen turns cautious on trucking stocks after the sector rallied briskly on a demand spike following the U.S. hurricanes.</li> <li>ArcBest (<a href='https://seekingalpha.com/symbol/ARCB' title='ArcBest Corporation'>ARCB</a> <font color='red'>-5.1%</font>), J.B. Hunt (<a href='https://seekingalpha.com/symbol/JBHT' title='J.B. Hunt Transport Services, Inc.'>JBHT</a> <font color='red'>-2.9%</font>) and Covenant Transportation Group (<a href='https://seekingalpha.com/symbol/CVTI' title='Covenant Transportation Group, Inc.'>CVTI</a> <font color='red'>-10.1%</font>) are all lowered to Market Perform from Outperform, while Werner Enterprises (<a href='https://seekingalpha.com/symbol/WERN' title='Werner Enterprises, Inc.'>WERN</a> <font color='red'>-2.5%</font>) is dropped to Underperform from Market Perform.</li> <li>The firm separated out C.H. Robinson and Landstar System (<a href='https://seekingalpha.com/symbol/LSTR' title='Landstar System, Inc.'>LSTR</a> <font color='red'>-0.7%</font>) as two stocks without the same stretched valuation.</li> <li>Source: Bloomberg</li><li>Previously: <a href=\"https://seekingalpha.com/news/3301164-cowen-singles-c-h-robinson-transportation-pick\" target=\"_blank\">Cowen singles out C.H. Robinson as transportation pick</a> (Oct. 16)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301181\" data-linked=\"Trucking stocks in retreat after Cowen weighs in\" data-tweet=\"$ARCB $ARCB $JBHT - Trucking stocks in retreat after Cowen weighs in https://seekingalpha.com/news/3301181-trucking-stocks-in-retreat-after-cowen-weighs-in?source=tweet\" data-url=\"https://seekingalpha.com/news/3301181-trucking-stocks-in-retreat-after-cowen-weighs-in\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301180\" data-ts=\"1508165211\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RIO\" target=\"_blank\">RIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301180-ft-rio-tinto-in-talks-to-sell-australia-new-zealand-aluminum-assets\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FT: Rio Tinto in talks to sell Australia, New Zealand aluminum assets</a></h4><ul>     <li>Rio Tinto (<a href='https://seekingalpha.com/symbol/RIO' title='Rio Tinto plc'>RIO</a> <font color='green'>+1%</font>) is <a href=\"https://www.ft.com/content/aa94ecea-6b85-3fe6-9ce9-2f43049b53fb\" target=\"_blank\">in advanced talks to sell</a> its aluminum assets in Australia and New Zealand to investment company GFG Alliance, <em>Financial Times</em> reports.</li>     <li>GFG's Sanjeev Gupta is said to covet Rio's Pacific aluminum business as he looks to build a global industrial conglomerate spanning metals, power, renewable energy and finance, but he could face competition from Century Aluminum (<a href='https://seekingalpha.com/symbol/CENX' title='Century Aluminum Company'>CENX</a> <font color='green'>+1.6%</font>), according to the report.</li>     <li>Rio reached its highest closing price on the Australian Stock Exchange since February 2014 today in the wake of China's record iron ore imports for September and <a href=\"https://seekingalpha.com/news/3300894-iron-ore-rallies-chinas-clean-air-push-hurts-local-supply\" target=\"_blank\">last Friday's surge</a> in the iron ore benchmark price.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301180\" data-linked=\"FT: Rio Tinto in talks to sell Australia, New Zealand aluminum assets\" data-tweet=\"$RIO $RIO $CENX - FT: Rio Tinto in talks to sell Australia, New Zealand aluminum assets https://seekingalpha.com/news/3301180-ft-rio-tinto-in-talks-to-sell-australia-new-zealand-aluminum-assets?source=tweet\" data-url=\"https://seekingalpha.com/news/3301180-ft-rio-tinto-in-talks-to-sell-australia-new-zealand-aluminum-assets\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:46 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301176\" data-ts=\"1508164765\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLSN\" target=\"_blank\">CLSN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301176-celsion-up-8-on-heat-study-publication-and-therapeutic-potential-of-thermodox-rfa\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Celsion up 8% on HEAT study publication and therapeutic potential of ThermoDox + RFA</a></h4><ul><li>Celsion (<a href='https://seekingalpha.com/symbol/CLSN' title='Celsion Corporation'>CLSN</a> <font color='green'>+8%</font>) perks up on modestly higher volume on the heels of its <a href=\"https://seekingalpha.com/pr/16968955-celsion-announces-publication-heat-study-manuscript-high-impact-journal-clinical-cancer\" target=\"_blank\">announcement </a>that a <a href=\"http://clincancerres.aacrjournals.org/content/early/2017/10/10/1078-0432.CCR-16-2433.long\" target=\"_blank\">manuscript </a>on its Phase 3 HEAT study assessing ThermoDox plus standardized radiofrequency ablation in hepatocellular carcinoma &#40;HCC&#41;&nbsp;has just been published in <em>Clinical Cancer Research</em>.</li><li>The company says results from the study, data from computer simulations and a <em>post hoc</em> subgroup analysis suggest a clearer understanding of ThermoDox's heat-based mechanism of action, specifically the longer the tissue is heated, the greater the doxorubicin concentration in tissue.</li><li>The article also explores the hypothesis that ThermoDox combined with radiofrequency ablation &#40;RFA&#41; standardized to a minimum dwell time of 45 minutes may increase overall survival &#40;OS&#41; in HCC patients.</li><li>To test the hypothesis, the company is conducting the Phase 3 <a href=\"https://clinicaltrials.gov/ct2/show/NCT02112656?intr=thermodox&amp;titles=optima&amp;spons=celsion&amp;rank=1\" target=\"_blank\">OPTIMA </a>study. The primary endpoint is OS over five years. According to ClinicalTrials.gov, the estimated primary completion date is November 2019.</li><li>At the company's recent R&amp;D Day, investigators presented data that showed a 58% improvement in OS from the ThermoDox/RFA combo compared to RFA alone with 37% less risk of death (hazard ratio = 0.63).</li></ul><div class=\"tiny-share-widget\" data-id=\"3301176\" data-linked=\"Celsion up 8% on HEAT study publication and therapeutic potential of ThermoDox + RFA\" data-tweet=\"$CLSN - Celsion up 8% on HEAT study publication and therapeutic potential of ThermoDox + RFA https://seekingalpha.com/news/3301176-celsion-up-8-on-heat-study-publication-and-therapeutic-potential-of-thermodox-rfa?source=tweet\" data-url=\"https://seekingalpha.com/news/3301176-celsion-up-8-on-heat-study-publication-and-therapeutic-potential-of-thermodox-rfa\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:39 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301177\" data-ts=\"1508164071\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OMC\" target=\"_blank\">OMC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301177-omnicomminus-1_9-morgan-stanley-cuts-to-underweight\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Omnicom -1.9% as Morgan Stanley cuts to Underweight</a></h4><ul>   <li>Omnicom (NYSE:<a href='https://seekingalpha.com/symbol/OMC' title='Omnicom Group Inc.'>OMC</a>) is <font color='red'>off 1.9%</font> with Morgan Stanley cutting to Underweight ahead of tomorrow's earnings, pointing to a secular slowdown in several advertising verticals that is bleeding through to the ad giant's results.</li>    <li>Retail, CPG and telecom have their own challenges that are pressuring those verticals, analyst Benjamin Swinburne says.</li>    <li>Street estimates are too high, he continues, expecting margin expansion that's getting more difficult to achieve.</li>    <li>He's trimmed his price target to $72 from $86 (implying 2.3% downside ahead), and also cut his price target on advertising rival Interpublic Group (<a href=\"http://seekingalpha.com/symbol/IPG\" target=\"_blank\">IPG</a> <font color='red'>-1.8%</font>) to $22 from $24, implying 7.6% upside. (h/t Bloomberg)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301177\" data-linked=\"Omnicom -1.9% as Morgan Stanley cuts to Underweight\" data-tweet=\"$OMC $OMC $IPG - Omnicom -1.9% as Morgan Stanley cuts to Underweight https://seekingalpha.com/news/3301177-omnicomminus-1_9-morgan-stanley-cuts-to-underweight?source=tweet\" data-url=\"https://seekingalpha.com/news/3301177-omnicomminus-1_9-morgan-stanley-cuts-to-underweight\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:27 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301102\" data-ts=\"1508162970\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EXEL\" target=\"_blank\">EXEL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301102-exelixis-cabometyx-successful-in-late-stage-liver-cancer-study-shares-ahead-17-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Exelixis&#39; Cabometyx successful in late-stage liver cancer study; shares ahead 17% premarket</a></h4><ul><li>Exelixis (NASDAQ:<a href='https://seekingalpha.com/symbol/EXEL' title='Exelixis, Inc.'>EXEL</a>) is up&nbsp;<font color='green'>17%</font>&nbsp;premarket on average volume in response to its <a href=\"https://seekingalpha.com/pr/16968634-exelixis-phase-3-celestial-trial-cabozantinib-meets-primary-endpoint-overall-survival\" target=\"_blank\">announcement </a>of positive results from a Phase 3 clinical trial, CELESTIAL, evaluating CABOMETYX (cabozantinib) in patients with advanced hepatocellular carcinoma &#40;HCC&#41;, an Orphan Drug indication.</li><li>The independent Data Monitoring Committee recommended that the trial be stopped early for efficacy. The primary endpoint was overall survival. Detailed results will be submitted for presentation at a future medical conference.</li><li>The company plans to file a supplemental New Drug Application (sNDA) with the FDA in Q1 2018.</li><li>The FDA approved CABOMETYX for the second-line treatment of kidney cancer in April 2016. The company's <a href=\"https://seekingalpha.com/pr/16968635-exelixis-announces-u-s-fda-grants-priority-review-cabometyx-cabozantinib-treatment-previously\" target=\"_blank\">marketing application</a> for first-line kidney cancer is currently under FDA review under Priority Review status with an action date of February 25, 2018.</li><li>Collaboration partner Ipsen (<a href='https://seekingalpha.com/symbol/IPSEY' title='Ipsen S.A. ADR'>OTCPK:IPSEY</a> <font color='green'>+3.9%</font>) is also up on the news.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301102\" data-linked=\"Exelixis&#39; Cabometyx successful in late-stage liver cancer study; shares ahead 17% premarket\" data-tweet=\"$EXEL $EXEL $IPSEY - Exelixis&#39; Cabometyx successful in late-stage liver cancer study; shares ahead 17% premarket https://seekingalpha.com/news/3301102-exelixis-cabometyx-successful-in-late-stage-liver-cancer-study-shares-ahead-17-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3301102-exelixis-cabometyx-successful-in-late-stage-liver-cancer-study-shares-ahead-17-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301172\" data-ts=\"1508162913\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MNI\" target=\"_blank\">MNI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301172-mcclatchyminus-3-revenue-shortfall-drives-q3-loss\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">McClatchy -3% as revenue shortfall drives Q3 loss</a></h4><ul>   <li>McClatchy (NYSEMKT:<a href='https://seekingalpha.com/symbol/MNI' title='The McClatchy Company'>MNI</a>) is <font color='red'>3% lower</font> after its <a href=\"https://seekingalpha.com/news/3301146-mcclatchy-misses-revenue\" target=\"_blank\">Q3 earnings</a> missed expectations on declining revenues, though the company pointed to audience gains.</li>    <li>Revenues fell 9.4% overall, and the company took large noncash charges of $230.9M tied mainly to a deferred tax valuation allowance, leading to a net loss of $238.9M (adjusted net loss was $5.9M).</li>    <li>Hurricane Irma had a negative impact on revenue, which would have been 9.1% excluding those effects, the company said.</li>    <li>It pointed to a slowing decline in EBITDA (which at $34.2M beat an expected $29.9M).</li>    <li>Audiences hit a record 89.3M unique visitors with many searching for hurricane news.</li>    <li>Revenue breakout: Advertising, $115.3M (down 13.4%); Audience, $87.1M (down 4.3%).</li>    <li><a href=\"http://www.mcclatchy.com/\" target=\"_blank\">Conference call</a> to come at noon ET.</li>    <li><a href=\"https://seekingalpha.com/pr/16969022-mcclatchy-reports-third-quarter-2017-results\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3301172\" data-linked=\"McClatchy -3% as revenue shortfall drives Q3 loss\" data-tweet=\"$MNI - McClatchy -3% as revenue shortfall drives Q3 loss https://seekingalpha.com/news/3301172-mcclatchyminus-3-revenue-shortfall-drives-q3-loss?source=tweet\" data-url=\"https://seekingalpha.com/news/3301172-mcclatchyminus-3-revenue-shortfall-drives-q3-loss\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:08 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301171\" data-ts=\"1508162667\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NHTC\" target=\"_blank\">NHTC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301171-natural-health-trends-falls-after-issuing-q3-sales-update\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Natural Health Trends falls after issuing Q3 sales update</a></h4><ul> <li>Natural Health Trends Corp. (<a href='https://seekingalpha.com/symbol/NHTC' title='Natural Health Trends Corp.'>NHTC</a> <font color='red'>-15.7%</font>) trades lower after announcing preliminary results for Q3.</li>   <li>The company estimates total revenue for the quarter to be $40.1M.</li><li>Deferred revenue at the end of the quarter was $3.6M vs. $4.0M at the end of Q2.</li>  <li>&ldquo;While our preliminary revenue estimate for the third quarter of 2017 reflects a year-over-year and quarter-over-quarter decline, we remain on track to revitalize sales growth,\" says president&nbsp;Chris Sharng.</li>  <li>\"Despite the challenging environment during the quarter, a number of our markets achieved double-digit sales growth including Peru, Europe, Southeast Asia and Japan,\" he adds.</li><li>Source: <a href=\"https://seekingalpha.com/pr/16968324-natural-health-trends-announces-third-quarter-2017-preliminary-revenue-estimate\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3301171\" data-linked=\"Natural Health Trends falls after issuing Q3 sales update\" data-tweet=\"$NHTC - Natural Health Trends falls after issuing Q3 sales update https://seekingalpha.com/news/3301171-natural-health-trends-falls-after-issuing-q3-sales-update?source=tweet\" data-url=\"https://seekingalpha.com/news/3301171-natural-health-trends-falls-after-issuing-q3-sales-update\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301170\" data-ts=\"1508162662\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DVA\" target=\"_blank\">DVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301170-lower-potential-income-exposure-to-charitable-premium-assistance-program-propels-davita\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lower potential income exposure to charitable premium assistance program propels DaVita, shares ahead 4%</a></h4><ul><li>DaVita (<a href='https://seekingalpha.com/symbol/DVA' title='DaVita HealthCare Partners Inc.'>DVA</a> <font color='green'>+4%</font>) says if its charitable premium assistance program was eliminated, an <a href=\"https://seekingalpha.com/pr/16968560-davita-provides-additional-information-regarding-patients-receiving-charitable-premium\" target=\"_blank\">unlikely scenario</a> in its view, annual operating income would be trimmed $100M - 250M, assuming that most patients with commercial insurance would continue coverage, either with their current plan or a new one.</li><li>~1,800 DaVita patients in the individual market segment receive charitable assistance. Most maintain their pre-end-stage renal disease &#40;ESRD&#41; coverage. The company says the majority would have access to premium tax credits and would be able to afford their premium without the charitable contribution. Nevertheless, it projects that annual operating income would be reduced by $45M - 90M if the program were discontinued.</li><li>In the commercial group segment, about 4,000 DaVita patients receive charitable premium assistance. About 55% are covered under employer-provided coverage and they receive charitable assistance to ease the financial burden of their co-pays, ~$200 - 300/month. The company believes most would continue coverage without the assistance.</li><li>The other 45% are on COBRA plans. The company believes many who could no longer afford the COBRA premium without financial help would qualify for and migrate to individual plans with premium tax credits, adding that a substantial portion would maintain coverage even without the assistance.</li><li>About 80% of the 19,000 DaVita patients in the government segment receive charitable premium assistance. The company believes that most would retain their Medicare coverage if the financial help was eliminated but they would likely lose their secondary (Medigap) coverage. It says the impact on operating income would be limited but there would be significant negative consequences for many patients.</li><li>Management will be prepared to answer additional questions during its Q3 earnings call.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3300153-davita-discloses-potential-450m-exposure-operating-income-charitable-premium-assistance\" target=\"_blank\">DaVita discloses potential $450M exposure to operating income from charitable premium assistance</a> (Oct. 10)</li></ul><div class=\"tiny-share-widget\" data-id=\"3301170\" data-linked=\"Lower potential income exposure to charitable premium assistance program propels DaVita, shares ahead 4%\" data-tweet=\"$DVA - Lower potential income exposure to charitable premium assistance program propels DaVita, shares ahead 4% https://seekingalpha.com/news/3301170-lower-potential-income-exposure-to-charitable-premium-assistance-program-propels-davita?source=tweet\" data-url=\"https://seekingalpha.com/news/3301170-lower-potential-income-exposure-to-charitable-premium-assistance-program-propels-davita\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301169\" data-ts=\"1508162430\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MTZ\" target=\"_blank\">MTZ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301169-mastecplus-6-on-1_5b-plus-pipeline-construction-award\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MasTec +6% on $1.5B-plus pipeline construction award</a></h4><ul>     <li>MasTec (<a href='https://seekingalpha.com/symbol/MTZ' title='MasTec, Inc.'>MTZ</a> <font color='green'>+5.9%</font>) is off to a strong start after announcing a <a href=\"https://seekingalpha.com/pr/16969177-mastec-announces-large-project-2018-pipeline-construction-award\" target=\"_blank\">large project pipeline construction award</a> with an expected contract value of more than $1.5B, with activity for the U.S.-based award expected to begin in 2018.</li>          <li>MTZ&nbsp;says it will provide further information regarding activity in its large project pipeline market, which includes recent oil and gas awards totaling nearly $2B, during its Q3 earnings call in early November.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301169\" data-linked=\"MasTec +6% on $1.5B-plus pipeline construction award\" data-tweet=\"$MTZ - MasTec +6% on $1.5B-plus pipeline construction award https://seekingalpha.com/news/3301169-mastecplus-6-on-1_5b-plus-pipeline-construction-award?source=tweet\" data-url=\"https://seekingalpha.com/news/3301169-mastecplus-6-on-1_5b-plus-pipeline-construction-award\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:00 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301165\" data-ts=\"1508162004\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MTSI\" target=\"_blank\">MTSI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301165-stifel-downgrades-macom-technology\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stifel downgrades Macom Technology</a></h4><ul><li>        Stifel <a href=\"http://www.briefing.com/DisplayArticle/ArticlePopup.aspx?ArticleId=IN20171016064049MTSI\" target=\"_blank\">downgrades</a> Macom Technology Solutions (NASDAQ:<a href='https://seekingalpha.com/symbol/MTSI' title='MACOM Technology Solutions Holdings, Inc.'>MTSI</a>) from Buy to Hold and drops the price target from $57 to $43.&nbsp;</li><li>        Firm cites management&rsquo;s expected near-term weakness in China that could last throughout this year.</li><li>               Other headwinds include cash flow generation challenges and poor capital management especially related to acquisitions.&nbsp;</li><li>               Macom shares are&nbsp;<font color='red'>down 7.89%</font>. &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3301165\" data-linked=\"Stifel downgrades Macom Technology\" data-tweet=\"$MTSI - Stifel downgrades Macom Technology https://seekingalpha.com/news/3301165-stifel-downgrades-macom-technology?source=tweet\" data-url=\"https://seekingalpha.com/news/3301165-stifel-downgrades-macom-technology\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301164\" data-ts=\"1508161934\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CHRW\" target=\"_blank\">CHRW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301164-cowen-singles-out-c-h-robinson-transportation-pick\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cowen singles out C.H. Robinson as transportation pick</a></h4><ul> <li>C.H. Robinson (<a href='https://seekingalpha.com/symbol/CHRW' title='C.H. Robinson Worldwide Inc.'>CHRW</a> <font color='red'>-0.1%</font>) is on watch after Cowen upgrades the transportation stock to Outperform from Market Perform. The ratings action stands out because Cowen downgraded four other transportation stocks today on valuation concerns.</li> <li>Cowen's new price target on C.H. Robinson of $97 reps 26% upside potential.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3301164\" data-linked=\"Cowen singles out C.H. Robinson as transportation pick\" data-tweet=\"$CHRW - Cowen singles out C.H. Robinson as transportation pick https://seekingalpha.com/news/3301164-cowen-singles-out-c-h-robinson-transportation-pick?source=tweet\" data-url=\"https://seekingalpha.com/news/3301164-cowen-singles-out-c-h-robinson-transportation-pick\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301161\" data-ts=\"1508160812\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JWN\" target=\"_blank\">JWN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301161-nordstrom-go-private-stumble-hangs-over-department-store-sector\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nordstrom go-private stumble hangs over department store sector</a></h4><ul> <li>The department store sector is on watch after Nordstrom (<a href='https://seekingalpha.com/symbol/JWN' title='Nordstrom Inc.'>JWN</a> <font color='red'>-3.2%</font>) pauses its go-private plans.</li> <li>The Nordstrom family is giving the go-private pursuit a pause for the rest of the year due to the difficulty in lining up financing.</li> <li>Shares of J.C. Penney (<a href='https://seekingalpha.com/symbol/JCP' title='J.C. Penney Company Inc.'>JCP</a> <font color='red'>-0.9%</font>), Kohl's (<a href='https://seekingalpha.com/symbol/KSS' title='Kohl&#39;s Corporation'>KSS</a> <font color='red'>-1%</font>), Macy's (<a href='https://seekingalpha.com/symbol/M' title='Macy&#39;s Inc.'>M</a> <font color='red'>-1%</font>), Sears Holdings (SHLD <font color='red'>-8.4%</font>) and Dillard's (<a href='https://seekingalpha.com/symbol/DDS' title='Dillard&#39;s Inc.'>DDS</a>) have swung up and down as Nordstrom has tested the go-private path. The difficulty of the department store operator in getting to the finish line could tamp down enthusiasm within the sector over other M&amp;A action.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3301150-nordstrom-5-percent-family-suspends-going-private-deal\" target=\"_blank\">Nordstrom down 5% as family suspends going-private deal</a> (Oct. 16)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301161\" data-linked=\"Nordstrom go-private stumble hangs over department store sector\" data-tweet=\"$JWN $JWN $JCP - Nordstrom go-private stumble hangs over department store sector https://seekingalpha.com/news/3301161-nordstrom-go-private-stumble-hangs-over-department-store-sector?source=tweet\" data-url=\"https://seekingalpha.com/news/3301161-nordstrom-go-private-stumble-hangs-over-department-store-sector\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301158\" data-ts=\"1508160595\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/C\" target=\"_blank\">C</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301158-citi-downgraded-to-sell-socgen-shares-down-1_25-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Citi downgraded to Sell at SocGen; shares down 1.25% premarket</a></h4><ul><li>Higher provisions in Citigroup's (NYSE:<a href='https://seekingalpha.com/symbol/C' title='Citigroup Inc.'>C</a>) credit-cards business is analyst Andrew Lim's chief concern. While conceding that part of the uptick is thanks to seasonal effects and the hurricanes, Lim says the trend has deteriorated over several quarters.</li><li>Lim also takes note of net interest margin flattening out in Q3 even though the Fed boosted rates. It raises questions of management's view of the bank's positive leverage to higher rates.</li><li>He downgrades to Sell from Hold.</li><li>Shares&nbsp;<font color='red'>down 1.25%</font>&nbsp;premarket</li><li>Source: Bloomberg's Felice Maranz</li></ul><div class=\"tiny-share-widget\" data-id=\"3301158\" data-linked=\"Citi downgraded to Sell at SocGen; shares down 1.25% premarket\" data-tweet=\"$C - Citi downgraded to Sell at SocGen; shares down 1.25% premarket https://seekingalpha.com/news/3301158-citi-downgraded-to-sell-socgen-shares-down-1_25-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3301158-citi-downgraded-to-sell-socgen-shares-down-1_25-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301157\" data-ts=\"1508160486\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VHC\" target=\"_blank\">VHC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301157-virnetx-announces-results-of-apple-patent-case-includes-1_20-per-device-update\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">VirnetX announces results of Apple patent case, includes $1.20 per device (update)</a></h4><ul><li>VirnetX (NYSEMKT:<a href='https://seekingalpha.com/symbol/VHC' title='VirnetX Holding Corporation'>VHC</a>) shares are&nbsp;<font color='green'>up 19.3%</font>&nbsp;premarket after the company <a href=\"https://seekingalpha.com/pr/16969156-virnetx-receives-courts-final-judgment-affirming-jurys-verdict-1_20-per-infringing-apple\" target=\"_blank\">announces</a> the court ruling in its first patent case against Apple.</li><li>The court denied all of Apple&rsquo;s motions and granted all of VirnetX&rsquo;s motions including a motion for willful infringement and a 50% enhanced royalty rate during the willfulness period. The rate increases from the jury appointed $1.20 to $1.80 per offending device.</li><li>The court awarded VirnetX enhanced damages of about $41.3M. The total award amount with willful infringement, interest, and court costs totals $439.7M.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3301015-virnetx-shares-plunge-ahead-court-document-release-update\" target=\"_blank\">VirnetX shares plunge ahead of court document release (update)</a> (Oct. 13)</li><li>Update: Apple (NASDAQ:<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a>) tells <a href=\"https://www.theverge.com/2017/10/16/16482568/apple-virnetx-facetime-patent-battle-loss-appeal-planned\" target=\"_blank\">The Verge</a> the company plans to appeal the ruling.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301157\" data-linked=\"VirnetX announces results of Apple patent case, includes $1.20 per device (update)\" data-tweet=\"$VHC $VHC $AAPL - VirnetX announces results of Apple patent case, includes $1.20 per device (update) https://seekingalpha.com/news/3301157-virnetx-announces-results-of-apple-patent-case-includes-1_20-per-device-update?source=tweet\" data-url=\"https://seekingalpha.com/news/3301157-virnetx-announces-results-of-apple-patent-case-includes-1_20-per-device-update\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>35&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301156\" data-ts=\"1508160456\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GRPN\" target=\"_blank\">GRPN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301156-grouponplus-2_4-cowen-takes-off-sell-sign\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Groupon +2.4% as Cowen takes off Sell sign</a></h4><ul>   <li>Groupon (NASDAQ:<a href='https://seekingalpha.com/symbol/GRPN' title='Groupon, Inc.'>GRPN</a>) is <font color='green'>up 2.4%</font> premarket after a boost to Market Perform by Cowen, which sees \"balanced expectations\" for the second half.</li>    <li>Billings growth, revenue and gross profit in Q2 all improved from the first quarter, analyst Thomas Champion notes, and new mobile-centric products could expand market penetration for the company.</li>    <li>He's raised his price target to $5.50 from $3.50, implying 19% upside.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301156\" data-linked=\"Groupon +2.4% as Cowen takes off Sell sign\" data-tweet=\"$GRPN - Groupon +2.4% as Cowen takes off Sell sign https://seekingalpha.com/news/3301156-grouponplus-2_4-cowen-takes-off-sell-sign?source=tweet\" data-url=\"https://seekingalpha.com/news/3301156-grouponplus-2_4-cowen-takes-off-sell-sign\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301155\" data-ts=\"1508160445\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301155-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/TRXC' title='TransEnterix, Inc.'>TRXC</a> <font color='green'>+78%</font>&nbsp;FDA's 510(k)&nbsp;<a href=\"https://seekingalpha.com/news/3301042-fda-clears-tranenterixs-robotic-surgery-system-senhance-shares-ahead-60-percent-hours\" target=\"_blank\">clearance</a>&nbsp;for its&nbsp;Senhance System.</li>     <li><a href='https://seekingalpha.com/symbol/RCON' title='Recon Technology, Ltd.'>RCON</a> <font color='green'>+26%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16968900-recon-bow-signed-sewage-treatment-strategic-cooperation-agreement\" target=\"_blank\">signing</a> a three-year strategic cooperation agreement with Beijing OriginWater Purification Engineering Technology.</li>     <li><a href='https://seekingalpha.com/symbol/LBIX-OLD' title='Leading Brands Inc'>LBIX-OLD</a> <font color='green'>+27%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/RT' title='Ruby Tuesday, Inc.'>RT</a> <font color='green'>+20%</font>&nbsp;on Q2 <a href=\"https://seekingalpha.com/news/3301128-leading-brands-reports-q2-results\" target=\"_blank\">result</a>.</li>     <li><a href='https://seekingalpha.com/symbol/EXEL' title='Exelixis, Inc.'>EXEL</a> <font color='green'>+16%</font>&nbsp;on&nbsp;Cabometyx&nbsp;<a href=\"https://seekingalpha.com/news/3301102-exelixis-cabometyx-successful-late-stage-liver-cancer-study-shares-ahead-17-percent-premarket\" target=\"_blank\">successful</a> in late-stage liver cancer study.</li>     <li><a href='https://seekingalpha.com/symbol/HIIQ' title='Health Insurance Innovations'>HIIQ</a> <font color='green'>+14%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3301129-health-insurance-innovations-reports-preliminary-q3-results-shares-ahead-16-percent-premarket\" target=\"_blank\">preliminary</a> Q3 results.</li>     <li><a href='https://seekingalpha.com/symbol/VHC' title='VirnetX Holding Corporation'>VHC</a> <font color='green'>+13%</font>&nbsp;on court document <a href=\"https://seekingalpha.com/news/3301015-virnetx-shares-plunge-ahead-court-document-release-update\" target=\"_blank\">release</a>.</li>     <li><a href='https://seekingalpha.com/symbol/XXII' title='22nd Century Group, Inc.'>XXII</a> <font color='green'>+10%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a> <font color='green'>+10%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/CARA' title='Cara Therapeutics Inc.'>CARA</a> <font color='green'>+9%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16968687-cara-therapeutics-announces-successful-end-phase-2-meeting-fda-v-cr845-chronic-kidney-disease\" target=\"_blank\">successful</a> completion of its End-of-Phase 2 Meeting with the U.S. Food and Drug Administration.</li>     <li><a href='https://seekingalpha.com/symbol/RWLK' title='ReWalk Robotics'>RWLK</a> <font color='green'>+8%</font>&nbsp;as it begins next phase of testing&nbsp;in pre-clinical study.</li>     <li><a href='https://seekingalpha.com/symbol/NETE' title='Net Element International, Inc.'>NETE</a> <font color='green'>+8%</font>&nbsp;on launching Same-Day ACH payment processing solutions.</li>     <li><a href='https://seekingalpha.com/symbol/AEMD' title='Aethlon Medical, Inc.'>AEMD</a> <font color='green'>+8%</font>&nbsp;on collaboration with iBio (<a href='https://seekingalpha.com/symbol/IBIO' title='iBio, Inc.'>IBIO</a>).</li>     <li><a href='https://seekingalpha.com/symbol/ABEO' title='Abeona Therapeutics Inc.'>ABEO</a> <font color='green'>+7%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16968915-abeona-announces-13_85m-grant-leading-sanfilippo-syndrome-foundations-clinical-development\" target=\"_blank\">receiving</a>&nbsp;<em>grant $13.85 million for the continued advancement of lead Sanfilippo gene therapy programs.</em></li>     <li><a href='https://seekingalpha.com/symbol/PZRX' title='PhaseRx'>PZRX</a> <font color='green'>+7%</font>&nbsp;on analyst <a href=\"https://seekingalpha.com/news/3301149-premarket-analyst-action-healthcare\" target=\"_blank\">action</a>.</li>     <li><a href='https://seekingalpha.com/symbol/ONCS' title='OncoSec Medical Incorporated'>ONCS</a> <font color='green'>+7%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/CLSN' title='Celsion Corporation'>CLSN</a> <font color='green'>+7%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/AU' title='AngloGold Ashanti Limited'>AU</a> <font color='green'>+6%</font>.</li>     <li>ETRM <font color='green'>+6%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/MNKD' title='MannKind Corporation'>MNKD</a> <font color='green'>+5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301155\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$TRXC $RCON $LBIX-OLD - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3301155-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3301155-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301153\" data-ts=\"1508160273\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301153-brexit-brinksmanship-pound-slumping\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Brexit brinksmanship has pound slumping</a></h4><ul><li>Brexit negotiations are headed for a \"catastrophic breakdown,\" unless the EU agrees this week to move on to trade agreements, <a href=\"http://www.zerohedge.com/news/2017-10-16/cable-plummets-report-brexit-talks-headed-catastrophic-breakdown-if-no-eu-compromise\" target=\"_blank\">reports Bloomberg</a>, citing a person with knowledge of the U.K.'s position.</li><li>U.K. Prime Minister Theresa May, says the source, took a political risk last month by promising to make payments towards the EU budget and settle the divorce bill, and she now needs something in return.</li><li>In the green for most of the session, cable (NYSEARCA:<a href='https://seekingalpha.com/symbol/FXB' title='CurrencyShares British Pound Sterling Trust ETF'>FXB</a>) is now modestly lower vs. the dollar at $1.3271. The FTSE is barely in the green.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/FXB' title='CurrencyShares British Pound Sterling Trust ETF'>FXB</a>, <a href='https://seekingalpha.com/symbol/EWU' title='iShares MSCI United Kingdom ETF'>EWU</a>, <a href='https://seekingalpha.com/symbol/GBB' title='iPath GBP/USD Exchange Rate ETN'>GBB</a>, <a href='https://seekingalpha.com/symbol/DBUK' title='Deutsche X-trackers MSCI United Kingdom Hedged Equity ETF'>DBUK</a>, <a href='https://seekingalpha.com/symbol/FKU' title='First Trust United Kingdom AlphaDex ETF'>FKU</a>, <a href='https://seekingalpha.com/symbol/EWUS' title='iShares MSCI United Kingdom Small Cap Index ETF'>EWUS</a>, <a href='https://seekingalpha.com/symbol/DXPS' title='WisdomTree United Kingdom Hedged Equity ETF'>DXPS</a>, <a href='https://seekingalpha.com/symbol/HEWU' title='iShares Currency Hedged MSCI United Kingdom ETF'>HEWU</a>, <a href='https://seekingalpha.com/symbol/QGBR' title='SPDR MSCI United Kingdom Quality Mix ETF'>QGBR</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3301153\" data-linked=\"Brexit brinksmanship has pound slumping\" data-tweet=\"$FXB $EWU $GBB - Brexit brinksmanship has pound slumping https://seekingalpha.com/news/3301153-brexit-brinksmanship-pound-slumping?source=tweet\" data-url=\"https://seekingalpha.com/news/3301153-brexit-brinksmanship-pound-slumping\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:24 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301152\" data-ts=\"1508160268\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WYNN\" target=\"_blank\">WYNN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301152-deutsche-bank-positive-on-wynn-resorts\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Deutsche Bank positive on Wynn Resorts</a></h4><ul> <li>Wynn Resorts (NASDAQ:<a href='https://seekingalpha.com/symbol/WYNN' title='Wynn Resorts, Limited'>WYNN</a>) is on the move after Deutsche Bank lifts its price target on the casino stock to $161 from $150.</li> <li>Analyst Carlo Santelli bases the PT boost off of better-than-anticipated results from Wynn Palace in Cotai. A number of initiatives at Wynn Palace are helping the casino increase traffic in the key premium mass market segment.</li><li>Sources: CNBC and Bloomberg</li> <li>WYNN <font color='green'>+1.52%</font> premarket to $144.49.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301152\" data-linked=\"Deutsche Bank positive on Wynn Resorts\" data-tweet=\"$WYNN - Deutsche Bank positive on Wynn Resorts https://seekingalpha.com/news/3301152-deutsche-bank-positive-on-wynn-resorts?source=tweet\" data-url=\"https://seekingalpha.com/news/3301152-deutsche-bank-positive-on-wynn-resorts\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301151\" data-ts=\"1508159594\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301151-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/AMPE' title='Ampio Pharmaceuticals, Inc.'>AMPE</a> <font color='red'>-14%</font>&nbsp;on announcing&nbsp;<a href=\"https://seekingalpha.com/pr/16968957-ampio-pharmaceuticals-inc-announces-pricing-registered-direct-offering\" target=\"_blank\">pricing</a>&nbsp;of registered direct offering.</li><li><a href='https://seekingalpha.com/symbol/OREX' title='Orexigen Therapeutics, Inc.'>OREX</a>&nbsp;<font color='red'>-13%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3301138-orexigen-18-percent-premarket-soft-q3-view-contrave\" target=\"_blank\">soft</a> Q3 view for Contrave.</li><li><a href='https://seekingalpha.com/symbol/TGTX' title='TG Therapeutics, Inc.'>TGTX</a>&nbsp;<font color='red'>-13%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3301125-enrollment-complete-tgs-late-stage-study-tgminus-1101-tgminus-1202-combo-cll\" target=\"_blank\">completion</a> of full enrollment in the UNITY-CLL Phase 3 trial.</li><li>ITUS <font color='red'>-7%</font>.</li><li><a href='https://seekingalpha.com/symbol/ZSAN' title='Zosano Pharma'>ZSAN</a> <font color='red'>-6%</font>.</li><li><a href='https://seekingalpha.com/symbol/JWN' title='Nordstrom Inc.'>JWN</a> <font color='red'>-4%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16969151-special-committee-nordstrom-board-confirms-update-nordstrom-family-group-regarding-potential\" target=\"_blank\">confirming</a> update regarding potential going private transaction.</li><li><a href='https://seekingalpha.com/symbol/ATRS' title='Antares Pharma Inc.'>ATRS</a> <font color='red'>-5%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3301151\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$AMPE $OREX $TGTX - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3301151-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3301151-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:13 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301150\" data-ts=\"1508159510\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JWN\" target=\"_blank\">JWN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301150-nordstrom-down-5-family-suspends-going-private-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nordstrom down 5% as family suspends going-private deal</a></h4><ul><li><a href='https://seekingalpha.com/symbol/JWN' title='Nordstrom Inc.'>JWN</a>&nbsp;<font color='red'>-5.2%</font>&nbsp;premarket</li><li>Source: <a href=\"https://seekingalpha.com/pr/16969151-special-committee-nordstrom-board-confirms-update-nordstrom-family-group-regarding-potential\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3301150\" data-linked=\"Nordstrom down 5% as family suspends going-private deal\" data-tweet=\"$JWN - Nordstrom down 5% as family suspends going-private deal https://seekingalpha.com/news/3301150-nordstrom-down-5-family-suspends-going-private-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3301150-nordstrom-down-5-family-suspends-going-private-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301149\" data-ts=\"1508159475\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AZN\" target=\"_blank\">AZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301149-premarket-analyst-action-healthcare\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket analyst action - healthcare</a></h4><ul><li>AstraZeneca (NYSE:<a href='https://seekingalpha.com/symbol/AZN' title='AstraZeneca Group plc'>AZN</a>) upgraded to Outperform by Credit Suisse.</li><li>Bluebird bio (NASDAQ:<a href='https://seekingalpha.com/symbol/BLUE' title='bluebird bio, Inc.'>BLUE</a>) upgraded to Outperform by Evercore ISI.</li><li>Aerie Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/AERI' title='Aerie Pharmaceuticals, Inc.'>AERI</a>) price target raised to $76 from $65 by Needham after FDA approval of Rhopressa.</li><li>Halozyme (NASDAQ:<a href='https://seekingalpha.com/symbol/HALO' title='Halozyme Therapeutics, Inc.'>HALO</a>) price target raised to $29 from $26 by Piper Jaffray.</li><li>Johnson &amp; Johnson (NYSE:<a href='https://seekingalpha.com/symbol/JNJ' title='Johnson & Johnson'>JNJ</a>) price target raised to $160 from $157 by Jefferies.</li><li>ANI Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ANIP' title='ANI Pharmaceuticals, Inc.'>ANIP</a>) price target raised to $66 from $60 by Canaccord Genuity.</li><li>Alkermes (NASDAQ:<a href='https://seekingalpha.com/symbol/ALKS' title='Alkermes plc'>ALKS</a>) downgraded to Equal Weight by Barclays.</li><li>Abiomed (NASDAQ:<a href='https://seekingalpha.com/symbol/ABMD' title='ABIOMED, Inc.'>ABMD</a>) downgraded to Neutral by BTIG Research.</li><li>PhaseRx (NASDAQ:<a href='https://seekingalpha.com/symbol/PZRX' title='PhaseRx'>PZRX</a>) downgraded to Neutral by Laidlaw.</li><li>Audentes Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/BOLD' title='Audentes Therapeutics'>BOLD</a>) downgraded to Neutral by Evercore ISI.</li><li>Bristol-Myers Squibb (NYSE:<a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a>) downgraded to Hold by Jefferies.</li><li>Trevena (NASDAQ:<a href='https://seekingalpha.com/symbol/TRVN' title='Trevena, Inc.'>TRVN</a>) downgraded to Equal Weight by Barclays.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301149\" data-linked=\"Premarket analyst action - healthcare\" data-tweet=\"$AZN $AZN $BLUE - Premarket analyst action - healthcare https://seekingalpha.com/news/3301149-premarket-analyst-action-healthcare?source=tweet\" data-url=\"https://seekingalpha.com/news/3301149-premarket-analyst-action-healthcare\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301145\" data-ts=\"1508159140\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CSTR\" target=\"_blank\">CSTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301145-capstar-financial-beats-0_12-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CapStar Financial beats by $0.12, beats on revenue</a></h4><ul><li>CapStar Financial (NASDAQ:<a href='https://seekingalpha.com/symbol/CSTR' title='CapStar Financial Holdings'>CSTR</a>): Q3 EPS of $0.35 <font color='green'>beats by $0.12</font>.</li><li>Revenue of $14.22M (+6.8% Y/Y) <font color='green'>beats by $0.34M</font>.</li><li>Shares <font color='green'>+2.78%</font> PM.</li><li><a href='https://seekingalpha.com/pr/16969096-capstar-financial-holdings-inc-announces-third-quarter-2017-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3301145\" data-linked=\"CapStar Financial beats by $0.12, beats on revenue\" data-tweet=\"$CSTR - CapStar Financial beats by $0.12, beats on revenue https://seekingalpha.com/news/3301145-capstar-financial-beats-0_12-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3301145-capstar-financial-beats-0_12-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:05 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301143\" data-ts=\"1508159018\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAPL\" target=\"_blank\">AAPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301143-keybanc-upgrades-apple-on-iphone-x-pricing\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">KeyBanc upgrades Apple on iPhone X pricing</a></h4><ul><li>        KeyBanc <a href=\"https://www.cnbc.com/2017/10/16/apple-upgraded-by-keybanc-because-1000-iphone.html\" target=\"_blank\">upgrades</a> Apple (NASDAQ:<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a>) from Sector Weight to Overweight with a $ price target.</li><li>               Analyst Andy Hargreaves says Apple has &ldquo;a more aggressive strategy&rdquo; with the high iPhone X entry price and &ldquo;storage step-up pricing&rdquo; that will bring in more gross profit than the firm expected.&nbsp;</li><li>                  Hargreaves expects FY18 iPhone ASP and gross margin at $760 and 39.5%, respectively, compared to the $725 and 38.6% consensus.    </li><li>               The analyst also ups his FY18 EPS estimate to $11.68 from $11.07 compared to the $11.03 consensus.&nbsp;</li><li>               Apple shares are&nbsp;<font color='green'>up 0.8%</font>&nbsp;premarket.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3301122-foxconn-starts-iphone-x-shipments-46_5k-units\" target=\"_blank\">Foxconn starts iPhone X shipments but only 46.5K units</a> (Oct. 16)</li></ul><div class=\"tiny-share-widget\" data-id=\"3301143\" data-linked=\"KeyBanc upgrades Apple on iPhone X pricing\" data-tweet=\"$AAPL - KeyBanc upgrades Apple on iPhone X pricing https://seekingalpha.com/news/3301143-keybanc-upgrades-apple-on-iphone-x-pricing?source=tweet\" data-url=\"https://seekingalpha.com/news/3301143-keybanc-upgrades-apple-on-iphone-x-pricing\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>31&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301138\" data-ts=\"1508158671\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OREX\" target=\"_blank\">OREX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301138-orexigen-down-18-premarket-on-soft-q3-view-for-contrave\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Orexigen down 18% premarket on soft Q3 view for Contrave</a></h4><ul><li>Thinly traded nano cap Orexigen Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/OREX' title='Orexigen Therapeutics, Inc.'>OREX</a>) slumps&nbsp;<font color='red'>18%</font>&nbsp;premarket on the heels of its <a href=\"https://www.sec.gov/Archives/edgar/data/1382911/000119312517310295/d476732d8k.htm\" target=\"_blank\">disclosure </a>that it expects U.S. sales of Contrave (naltrexone HCl/bupropion HCl extended-release) to be $17.0M - 18.0M in Q3, down sequentially from Q2's $20.7M.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301138\" data-linked=\"Orexigen down 18% premarket on soft Q3 view for Contrave\" data-tweet=\"$OREX - Orexigen down 18% premarket on soft Q3 view for Contrave https://seekingalpha.com/news/3301138-orexigen-down-18-premarket-on-soft-q3-view-for-contrave?source=tweet\" data-url=\"https://seekingalpha.com/news/3301138-orexigen-down-18-premarket-on-soft-q3-view-for-contrave\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301134\" data-ts=\"1508157915\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RT\" target=\"_blank\">RT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301134-ruby-tuesday-agrees-to-buyout-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ruby Tuesday agrees to buyout deal</a></h4><ul> <li>Ruby Tuesday (NYSE:<a href='https://seekingalpha.com/symbol/RT' title='Ruby Tuesday, Inc.'>RT</a>)&nbsp;announces that it agreed to be acquired by NRD Capital for $2.40 per share in a deal valued at $335M including debt obligations.</li>  <li>The transaction has been unanimously approved by Ruby Tuesday&rsquo;s board.</li><li>The acquisition is expected to be completed during Q1 of 2018.</li><li>RT  <font color='green'>+20.60%</font> premarket to  $2.40.</li><li>Source: <a href=\"https://seekingalpha.com/pr/16968972-ruby-tuesday-acquired-nrd-capital-2_40-per-share\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3301134\" data-linked=\"Ruby Tuesday agrees to buyout deal\" data-tweet=\"$RT - Ruby Tuesday agrees to buyout deal https://seekingalpha.com/news/3301134-ruby-tuesday-agrees-to-buyout-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3301134-ruby-tuesday-agrees-to-buyout-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:45 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301132\" data-ts=\"1508157731\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SHLDQ\" target=\"_blank\">SHLDQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301132-sears-loses-key-board-member\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sears loses key board member</a></h4><ul> <li>Sears Holdings (SHLD)&nbsp;announces that&nbsp;Bruce Berkowitz&nbsp;will step down from department store company's board of directors on October 31.</li><li>Berkowitz, who serves as the chief investment officer of Fairholme Capital Management, joined the Sears board last year.</li>   <li>SHLD  <font color='red'>-2.51%</font> premarket to  $6.60.</li><li>Source: <a href=\"https://seekingalpha.com/pr/16968962-sears-holdings-announces-change-board-directors\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3301132\" data-linked=\"Sears loses key board member\" data-tweet=\"$SHLDQ - Sears loses key board member https://seekingalpha.com/news/3301132-sears-loses-key-board-member?source=tweet\" data-url=\"https://seekingalpha.com/news/3301132-sears-loses-key-board-member\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>155&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}